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ABSTRACT 
Advancements in prognostication have improved the subdivision of chronic 
lymphocytic leukaemia (CLL) into diverse prognostic subgroups. In CLL, IGHV 
unmutated and IGHV3-21 genes are associated with a poor-prognosis, conversely, 
IGHV mutated genes with a favourable outcome. The finding of multiple CLL 
subsets expressing ‘stereotyped’ B-cell receptors (BCRs) has suggested a role for 
antigen(s) in leukemogenesis. Patients belonging to certain stereotyped subsets share 
clinical and biological characteristics, yet limited knowledge exists regarding the 
genetic and epigenetic events that may influence their clinical behaviour. This thesis 
aimed to, further investigate Swedish IGHV3-21-utilising patients, screen for genetic 
and DNA methylation events in CLL subgroups/subsets and study DNA methylation 
over time and within different CLL compartments. 
In paper I, IGHV gene sequencing of 337 CLL patients from a Swedish 
population-based cohort revealed a lower (6.5%) IGHV3-21 frequency relative to 
previous Swedish hospital-based studies (10.1-12.7%). Interestingly, this frequency 
remained higher compared to other Western CLL (2.6-4.1%) hospital-based cohorts. 
Furthermore, we confirmed the poor-outcome for IGHV3-21 patients to be 
independent of mutational and stereotypy status. 
In paper II, genomic events in stereotyped IGHV3-21-subset #2, IGHV4-34-
subset #4 and subset #16 and their non-stereotyped counterparts were investigated via 
SNP arrays (n=101). Subset #2 and non-subset #2 carried a higher frequency of 
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events compared to subset #4. A high frequency of del(11q) was evident in IGHV3-
21 patients particularly subset #2 cases, which may partially explain their poor-
prognosis. In contrast, the lower prevalence of aberrations and absence of poor-
prognostic alterations may reflect the inherent low-proliferative disease seen in subset 
#4 cases. 
In papers III and IV, differential methylation profiles in IGHV mutated and 
IGHV unmutated patients were identified using DNA-methylation microarrays. CLL 
prognostic genes (CLLU1, LPL), tumor-suppressor genes (TSGs) (ABI3, WISP3) and 
genes belonging to TGF-ß and NFkB/ TNFR1 pathways were differentially 
methylated between the subgroups. Additionally, the re-expression of methylated 
TSGs by use of methyl and deacetyl inhibitors was demonstrated. Interestingly, 
analysis of patient-paired diagnostic/follow-up samples and patient-matched lymph 
node (LN) and peripheral blood (PB) cases revealed global DNA methylation to be 
relatively stable over time and remarkably similar within the different compartments. 
Altogether, this thesis provides insight into the aberrant genomic and DNA 
methylation events in divergent CLL subgroups. Moreover this thesis helps 
distinguish the extent to which DNA methylation changes with respect to time and 
microenvironment in CLL. 
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1:  INTRODUCTION 
Chronic lymphocytic leukaemia (CLL) is a malignant clonal disorder characterised 
by the accumulation of mature, functionally impaired neoplastic CD5+ B cells. 
Originating in the bone marrow these cells slowly progress to infiltrate the peripheral 
blood, lymph nodes and spleen. At both the clinical and biological level, CLL is 
highly heterogeneous in nature. This heterogeneity gives rise to highly divergent 
disease courses, ranging from an asymptomatic disease in some patients to an 
aggressive and rapidly fatal condition in others.1 Determination of the events 
contributing to CLL heterogeneity are key to identifying new prognostic markers that 
in turn will lead to better subdivision of CLL patients, allowing better implementation 
of optimal treatment regimes. 
Over the past twenty years, studies of the B cell receptor (BCR) molecule on CLL 
cells have denoted this molecule as a key player in CLL leukemogenesis and 
prognostication. For instance, the mutation status of the immuno-globulin heavy 
chain variable region gene (IGHV) has been established as one of the most reliable 
prognostic markers in CLL.2,3 Moreover, studies characterising the molecular 
structure of immunoglobulin (IG) gene re-arrangements support the notion that 
certain CLL subsets sharing a distinct clinical outcome present with highly similar IG 
rearrangements that may recognise a common antigen and confer a growth advantage 
to the CLL clone.4-6 In certain cases, other factors such as recurrent genomic 
alterations are known to contribute to CLL pathogenesis,7 however knowledge of 
 2 
aberrant DNA methylation events in this disease is limited. Hence, this thesis will 
focus on the relationship between the BCR structure, global genomic and DNA 
methylation events that may contribute to CLL leukemogenesis in different 
prognostic subgroups of CLL patients. 
1.1: Chronic lymphocytic leukaemia 
1.1 i: Epidemiology and aetiology 
Today, CLL represents ~30-40% of all leukaemias and is the most commonly 
encountered adult leukaemia in the Western world.8 Demonstrating a gender bias, the 
incidence of CLL is almost twice that in men as in women.9,10 In Sweden alone, ~500 
cases are diagnosed annually.11 The median age of CLL diagnosis is ~70 years, 
however a third of patients are younger than 60 years of age at diagnosis.10,11 First-
degree relatives of patients with CLL can have a 7-8.5 fold increased risk of 
developing CLL and a 2-fold increase for other lymphoproliferative diseases, 
suggesting a shared genetic component in familial CLL cases.12-15 
To date, the aetiology of CLL is still largely unknown, however a number of linkage 
studies have implicated some susceptibility loci in CLL. For instance, recent 
investigations have identified susceptibility loci at 2q13 2q37.1, 6p25.3, 11q24.1, 
15q23 and 19q13.32 thus providing the first evidence for the existence of common, 
low-penetrance susceptibility loci in sporadic CLL.16-18 Monoclonal B lymphocytosis 
(MBL), a condition characterised by the presence of <5.0x x109 clonal B cells per 
litre of peripheral blood (PB), is now suspected to represent the pre-clinical stage of 
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CLL. MBL is common among the general population, occuring in 3-5% of 
individuals over the age of 50 years.19-22 MBL can be categorised in to three 
immunophenotypes; i) CLL-like MBL, CD5 positive with low CD20 expression, ii) 
double positive CD5/CD20 MBL, resembling atypical CLL and iii) CD5 negative 
MBL.20,22 CLL-like MBL is the most frequent MBL immunophenotype encountered. 
Nevertheless, it must be kept in mind, that in the vast majority of MBL cases CLL 
will not ultimately emerge.21 Unlike other forms of leukaemia, only suggestive 
relationships between exposure to pesticides and certain solvents such as benzene 
have been indicated in CLL aetiology, thus the effect of hazardous environmental 
substances warrants further investigation.23,24 
CLL is thought to be driven by a multistep pathogenic process. This involves the 
evolution of CLL cells over time, gaining genomic and epigenetic alterations along 
their evolutionary path to become increasingly tumourigenic. At each step, CLL is 
driven by the combined contribution of intrinsic CLL defects with tumour promoting 
extrinsic microenvironmental factors to finally form fully fledged CLL. However, the 
specific nature and exact timing of initiating/transforming events in CLL 
pathogenesis remain elusive.25-27 Some of these elements contributing to CLL 
pathogenesis will be discussed in detail within the following sections. 
1.1 ii: Diagnosis 
The most characteristic feature of CLL is a peripheral blood B lymphocytosis of >5.0 
x109/L.28 Morphologically, CLL lymphocytes are smaller than normal B lymphocytes 
(Figure 1A). Furthermore, CLL cells appear to be more fragile resulting in the 
formation of characteristic "smudge" cells on a blood film preparation.29 
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Interestingly, some reports claim that the amount of smudge cells found in routine 
analysis may in fact be an independent prognostic factor for CLL.30 
Immunophenotypically, CLL monoclonal B cells typically express CD5, CD19, 
CD20, CD23 and faint levels of surface Ig (sIg).28,31 The clinical features of CLL 
such as lymphadenopathy and splenomegaly are generally indicative of later disease 
stages where these symptoms arise due to the accumulation of lymphocytes in the 
bone marrow (BM), spleen, lymph nodes (LN) and liver.9,32,33 
Hypogammaglobulinemia is also common in late CLL disease and is associated with 
an increased susceptibility to infection.34 
 
 
 
Figure 1A. May-Grünwald-Giemsa staining of CLL cells in the bone marrow. 
1.1 iii: Staging 
In clinical practice, two staging systems are used at present, Rai and Binet staging, 
however both of these systems have a limited ability to predict the clinical course at 
an early stage of the disease. This is due to the fact that these systems are dependent 
on the appearance of clinical symptoms which often occur late in disease.35,36 At 
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diagnosis, the majority of CLL patients are asymptomatic and it is only through 
routine testing that CLL is identified in these cases. Approximately 30-50% of these 
patients with an indolent CLL at diagnosis will progress, however predicting which 
patients will progress is uncertain when using such clinical staging systems.37 
Therefore, the need for new highly sensitive, specific and easily attainable prognostic 
markers is warranted. 
1.1 iv: Infectious complications in CLL 
Infectious complications play a major role in the mortality of CLL patients. These 
complications come secondary to the immune defects associated with primary CLL 
disease and secondary to immunosuppression caused by certain treatments. In fact, 
about 80% of CLL patients will experience infectious complications at some point 
during their disease that can severely reduce patient quality of life. Moreover, 50-
60% of patients will die due to infection. Some examples of commonly contracted 
infections are bacteremias and pneumonia caused by Streptococcus pneumoniae, 
Haemophilus influenzae, Legionella pneumophila, Staphylococcus aureus, 
Salmonella, and others. Herpes viruses are also commonly encountered in CLL 
patients.34 For instance, Epstein-Barr virus (EBV) can be a severe complication in 
some CLL cases, moreover it is thought to be involved in the transformation of CLL 
to aggressive Richters syndrome.38-40 
1.1 v: Treatment  
Currently, no outright cure for CLL exists, however various treatment strategies are 
employed. Asymptomatic CLL patients undergo a watch and wait approach, where 
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treatment is only administered upon evidence of progressive or symptomatic 
disease.28,41 The co-morbidity and fitness status of patients is taken into consideration 
prior to the selection of a particular treatment regime.41 Patients with active disease, 
that is patients with B symptoms, cytopenias and or complications from 
lymphadenopathy, hepatomegaly, splenomegaly and or a lymphocyte doubling time 
of <6 months are considered for treatment. Treatment with chlorambucil, an 
alkylating agent has been considered a front line therapy for CLL for many decades 
and remains an appropriate treatment today particularly in frail CLL patients.41 In the 
recent past, fludarabine, a purine analogue in combination with cyclophosphamide, an 
alkylating agent was deemed the standard first line therapy for CLL patients.42,43 
Together fludarabine, and cyclophosphamide, work jointly to inhibit DNA synthesis 
and initiate cell death.44 In some instances CLL patients may become refractory to 
such combination chemotherapy treatment.45 In these cases, the additional use of 
rituximab a monoclonal anti-CD20 antibody can improve the survival for such 
patients.41 Hence fludarabine in combination with cyclophosphamide and rituximab 
(FCR) is now considered the first line treatment of choice for fit CLL patients with 
active disease.41 
 
Choice of therapy not only depends on disease stage and patient fitness and 
performance, it depends on the patient’s cytogenetic profile. New evidence 
demonstrates that patients with deletion 11q can overcome the poor prognosis 
traditionally attributed to this genomic alteration when treated with FCR. More 
specifically, del(11q) patients treated with FCR have shown high rates of response, 
survival and relapse free survival.46 In contrast, patients carrying del(17p) or p53 
mutation have comprimisied function of their DNA damage response pathway hence, 
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treatment of such patients with conventional chemotherapy agents such as fludarabine 
and cyclophosphamide that work through this pathway will not respond.41 Even with 
FCR therapy these patients are shown to have a short progression free survival. In 
these cases, the use of anti-CD52 (Alemtuzumab) antibodies can be effective.47 High 
dose methyl-prednisolone in combination with alemtuzumab has also shown to be 
effective in aggressive CLL patients with p53 defects.48 Today, the only available 
potentially curative treatment is the use of allogenic stem cell transplantation; 
however this is solely considered for younger patients with unfavourable prognostic 
markers.41,49  
1.2: Normal B cells and B cell development 
In order to comprehend CLL pathogenesis, it is fundamental to understand the 
function of normal B cells and the processes of normal B cell development, IG gene 
rearrangement and B cell communication with antigen. B cells are the main cellular 
components of the adaptive immune response that augment humoral immunity 
through the production of antibodies. These cells function as key immune surveyors 
that recognize foreign antigens and generate specific antibody responses that are 
adapted to aid the elimination of specific invading pathogens. In order to produce 
antibodies that specifically bind antigens, the B cell must undergo a process of 
differentiation, a hierarchical pathway of development where each step is 
characterised by a specific pattern of cell surface markers.50 B cell maturation occurs 
in the bone marrow where stimulation from stromal cells and cytokines51,52 induce the 
differentiation of pro B cells expressing CD43, CD19 and CD10 from stem cells. 
Further maturation to the pre B cell stage denotes the earliest cell type synthesising a 
 8 
detectable IG, the cytoplasmic µ heavy chain. This µ heavy chain associates with 
surrogate light chains and Igα and Igβ signal transducer molecules to form the pre 
BCR.50,53 
The next stage involves the production of the kappa or lambda light chains. These 
light chains complex with µ heavy chains to produce IgM on the surface of the B cell 
at the immature B lymphocyte stage. At this stage, these cells do not respond to 
antigen, in fact on encountering antigen these cells may enter apoptosis or an anergic 
state. The transition from immature to mature cells is marked by the co-expression of 
µ and δ heavy chains producing membrane bound IgM and IgD, and this is 
accompanied by mature functional competence. Subsequently, fully mature B cells 
enter the circulation and lymphoid organs where they await antigen activation. Upon 
antigen encounter, the naïve B cell initiates cell signaling resulting in growth and 
proliferation of the B cell. This creates an amplified clone of plasma cells that secrete 
the antigen-specific Ig. Furthermore, following activation, B cells leave a lasting 
impression in the form of memory cells. These cells persist in circulation to produce a 
more rapid immune response should they encounter future challenges by the same 
antigen.50,53 
1.2 i: Structure of the immunoglobulin molecule 
The IG molecule is a membrane protein complex that is composed of two IG heavy 
chains and two IG light chains (Figure 1B).54 Fundamental to the generation of a 
diverse IG repertoire is the variable (V) region of the IG molecule. This region is 
generated through a distinct process of gene recombination events at both the IG 
heavy chain (IGH) and light chain (LC) loci known as VDJ recombination (see 
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below). The V region is characterized by conserved framework regions (FWR) 
integrated among highly variable complementarity determining regions (CDRs), 
CDR1, CDR2 and CDR3. In particular, the CDR3 is the most hypervariable region of 
the IG molecule that is formed through the joining of three IG gene segments, the V, 
diversity (D) and joining (J) gene segments (Figure. 1B).54,55 Thus, the CDR3 serves 
as the main player in determining IG specificity at the antigen binding groove.50 As 
such, IG constant regions (C) do not partake in antigen specificity; instead they 
constitute the isotype of the IG and determine the effector function of the IG. These 
regions may bind complement and receptor proteins to augment processes such as 
lysis, opsonisation and cell de-granulation.50 
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Figure 1B. Immunoglobulin structure ,VDJ recombination of the IGH locus and a 
representation of the heavy and light chain CDR3. 
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1.2 ii: VDJ recombination 
As mentioned, the intricate process of VDJ recombination is a complex mechanism 
involving a series of sequential rearrangements that play key roles in IG diversity.50,56 
In short, the V region of the heavy chain is created by assembling distinct variable 
(IGHV), diversity (IGHD) and joining (IGHJ) gene segments. There are 123-129 
IGHV gene segments available for recombination, however only 38-46 of these are 
functional gene segments. Moreover, 23 IGHD and 6 IGHJ functional gene segments 
as well as 9 constant (IGHC) gene segments are available for rearrangement (Figure 
1B).54,57,58 Rearrangement of the IGH locus commences at the pro B cell stage. On 
maturing to the pre B cell stage, the rearranged IGH complexes with a µ constant 
region to form IgM on the B cell surface.50 
In addition, rearrangement of the kappa (IGK) and lambda (IGL) light chain loci 
initiates during the pre-B cell stage, however only one specificity will be presented 
(kappa or lambda) on the cell surface of the mature B cell. Unlike rearrangement 
events at the IGH locus, only the joining of distinct V and J gene segments occurs at 
the IGK and IGL loci. In total, 36-40 functional IGKV, 5 IGKJ and one IGKC genes 
are available for recombination. At the IGL locus, 29-33 functional IGLV genes, 4-5 
IGLJ and 4-5 IGLC genes are available for rearrangement. Due to the lack of D genes 
at the light chain loci, the level of diversity is less than that observed at the IGH 
locus.50,54,58 
In short, the VDJ recombination mechanism is initiated by double stranded DNA 
breaks introduced by two lymphocyte specific recombination activating gene (RAG) 
enzymes, RAG 1 and RAG2.59-61 These enzymes work by forming a complex that 
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specifically recognises recombination signal sequences (RSS) that flank the coding 
V, D and J segments. These RSSs are made up of 3 distinct elements; a conserved 
heptamer and a nonamer separated by a spacer element of 12bp or 23bp.57,59,60 The 
length of this spacer element plays a key role in driving recombination specificity.62 
This is explained by the 12/23 spacer rule that states that only pairs of dissimilar 
spacer RSSs are efficiently recombined, so that spacers of 12 nucleotides will only be 
recombined with spacers containing 23 nucleotides.56,63 In accordance with the 12/23 
spacer recombination rule, a D gene segment will first combine with a J gene segment 
forming a DJ complex. Following DJ joining a V gene will join to the DJ segment 
forming a VDJ complex.50 
After the above recombination events have taken place, DNA repair mechanisms are 
employed to mend DNA breaks. DNA-dependent protein kinase complexes (DNA-
PK) are recruited to the broken DNA ends.62 Here, the DNA-PK recruits several other 
proteins and DNA polymerases to the free ends. On aligning of the two free DNA 
ends, the DNA-PK complex recruits the enzyme terminal deoxynucleotidyl 
transferase (TdT).64 TdT works to add random non-templated (n) nucleotides to the 
free DNA ends thus generating further IG diversity. Alternatively, deletion of 
nucleotides through exonuclease activity can provide a further layer of diversity at 
these junctional regions. Finally, DNA polymerases may insert additional nucleotides 
as needed to make the two ends compatible for joining. A ligase IV enzyme finally 
links DNA strands on opposite ends of the break to each other, completing the joining 
process.59,64 
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1.2 iii : The germinal center reaction and somatic hypermutation 
Secondary lymphoid organs such as the lymph node and spleen provide unique 
micro-environmental niches to allow naïve B cells the chance to encounter antigen, 
proliferate and produce specific antibodies in a process termed the germinal centre 
(GC) reaction (Figure 1C). Within these lymphoid organs are highly specialized GC 
follicles that provide niches encompassing a network of antigen presenting cells, co-
stimulator cells and cytokines. The GC reaction is initiated when the naïve B cell 
encounters antigen in the extra follicular spaces. Upon activation of the cell it moves 
to T helper cell zones. On recognizing the antigen, T helper cells produce CD40L 
which binds to the B cell CD40 receptor to promote B cell activation.65 This induces 
the B cell to transform into a highly proliferative centroblast within the dark zone of 
the GC follicle.65 In an effort to generate antibodies with a higher affinity to the 
initiating antigen, the process of somatic hypermutation (SHM) refines the sequences 
of the BCRs by introducing single nucleotide mutations randomly into the IG 
genes.66-68 In fact, SHM is a highly specialized process that occurs at a rate 106 times 
higher than spontaneous mutation.66,69 At this stage, B cells acquiring 
disadvantageous SHM patterns will die by apoptosis.70 However, those that acquire 
favourable antibody mutations move to the light zone of the follicle and are termed 
noncycling centrocytes.71 These centrocytes bind their cognate antigen with the help 
of follicular dendritic cells and T cells to differentiate into plasma or memory B 
cells.65,72 Although GCs are considered the principal sites capable of sustaining SHM, 
they are not thought to be the sole sites of such activity. It is thought that SHM may 
occur outside of the GC and independently of T cell help.73-76 For instance, it has 
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been suggested that B cells contained within the extra follicular marginal zone (MZ) 
of the spleen can also undergo SHM.73-76 
 
 
Figure 1C. The germinal centre reaction 
 
SHM represents a second mode of IG diversification after VDJ recombination. The 
process of SHM allows a further increase in IG diversity and the production of IGs 
with a higher specificity,77 however, knowledge of the exact mechanisms governing 
SHM are incomplete. SHM is known to involve the activation of induced cytidine 
deaminase (AID), an enzyme that works to deaminate cytosine bases to uracil in 
single stranded DNA creating a U:G mismatch.77 The mismatch is recognised by the 
cell’s DNA repair enzymes that excise the uracil base, however, error prone 
polymerases that work to fill in this gap result in the formation of mutations at this 
site.77 These mutations are mainly substitution mutations; however insertions and 
deletions also occur. Mutations are more commonly encountered in the CDR 
sequences where certain hotspots within these regions appear to be targeted more 
often to other regions.78-82 
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1.2 iv: Immunoglobulin diversity 
As mentioned, the vast variety of unique IG molecules making up the human Ig 
repertoire is partially given by the intricate processes of VDJ recombination, SHM 
and non-templated (n) and palindromic (p) nucleotide addition/excision at junctional 
borders. In fact, due to these processes, the likelihood of finding two identical BCRs 
is negligible. More specifically, when considering all permutations of V, D and J 
genes at the IGH locus, the likelihood of the same VDJ
 
recombination event 
presenting in normal healthy persons is 1 in 6348. Taking into account the chances 
that individuals carrying the same heavy chain carry the same kappa or lambda 
rearrangement the probability further diminishes to approximately 1 in 2.3 million. 
Finally, SHM events and the enzymatic addition and or removal of n and p 
nucleotides at junctional regions further reduces the probability of two healthy 
persons expressing identical BCRs to 2.3x1012.58 
1.3: The CLL cell and CLL pathogenesis 
On a blood film, CLL cells appear as small mature B lymphocytes containing a dense 
nuclear structure, partially aggregated chromatin and a narrow rim of cytoplasm.28 
However, CLL cells have intrinsic BCR signalling defects that are suggested to be 
characterized in some cases by truncated CD79b Ig domains,83 defective assembly,84 
glycosylation and folding of µ and CD79a chains.85 In other cases, somatic mutations 
in the cytoplasmic domain of CD79b have also beed described.85,86 These 
impairments may result in a low surface Ig expression and an inability to engage in 
effective signal transduction, jeopardising the ability of the CLL cell to undergo 
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apoptosis. Moreover, the high expression of the anti-apoptotic BCL2 family 
described in CLL87 and the up-regulation of the cell cycle arrest protein p27KIP may 
aid the accumlation of the CLL clone.88 Further propogated by continuous CLL cell 
proliferation in lymph nodes,89 CLL cells thrive and out-compete normal B cells. 
Once released to the peripheral blood, it is thought that CLL cells continually re-
circulate to the secondary lymphoid tissues, to receive growth and survival 
promotional signals from accessory cells, cytokines and antigens contained within the 
microenvironment. One theory proposes genetic and epigenetic alterations to act as 
early initiating/driving events in CLL transformation.26,90-93 In this model, 
microenvironmental extrinsic signals merely provide a support mechanism to the 
CLL cells, whereby antigen(s) is proposed to administer a chronic stimulation to 
BCR receptive CLL cells, propelling the clone along its tumorigenic path. In an 
opposing theory, antigen is suggested to act as the key culprit in CLL initiation, 
whereby long lived CLL cells acquire pathogenic genomic and epigenetic alterations 
as secondary hits over time. Despite the lack of knowledge about the order and 
sequence of such tumorigenic events, the proposed interplay between genomics, 
epigenomics and microenvironment suggests a complex multistep tumorigeneis 
model in CLL. However, key to this model is assessing the CLL cell of origin which 
to date remains elusive.25,27,94 
1.3 i: CLL cell of origin 
Over the past two decades the perception of the candidate cell(s) of origin for CLL 
has changed. Initially it was believed that a naive CD5+ B cell was the originator of 
CLL. However, the discovery of divergent CLL subgroups (see prognostic markers 
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section), IGHV mutated CLL, characterised by SHM of their IGHV genes and IGHV 
unmutated CLL, characterised by the lack of SHM at their IGHV genes altered this 
opinion. This finding lead to the hypothesis that unmutated CLL cells were derived 
from CD5+ naïve pre GC B cells, whereas mutated CLL derived from antigen 
experienced post GC memory B cells.2,3 In the recent past, it has been suspected that 
both mutated and unmutated CLL cases derive from antigen experienced B cells, as 
CLL cells were shown to have a similar gene expression profile to that of antigen 
experienced memory B cells.95 The candidate single cell origin of CLL is considered 
to be the marginal zone (MZ) B cell. The MZ B cell shares many CLL cell features 
such as, an active membrane phenotype, and BCRs encoded by either mutated or 
unmutated genes. Moreover, MZ B cells are also shown to demonstrate both poly and 
autoreactivity. Finally like CLL cells, these MZ B cells can respond to T cell 
dependent and independent antigens.25,75,94 
Nowadays however, the notion of a single cell of origin is being challenged.27 Given 
the fact that IGHV mutated and unmutated CLL have previously been shown to have 
rather similar gene expression profiles, it is now suspected that perhaps the activated 
state of CLL cells may mask larger gene expression differences between these 
subgroups.27 If this is the case, then conceivably it is more likely that mutated and 
unmutated CLL derive from two independent cell origins. Since CLL leukemogenesis 
is considered to follow a long stepwise process perhaps spanning several steps in B 
cell development, the prospect arises that transformation can occur anytime during B 
cell maturation once IG heavy chain is expressed.27 Theoretically, this opens up the 
possibility that CLL could be derived from multiple cell precursors.27 Today, it has 
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been suggested that the propensity to generate CLL clonal B cells is already decided 
at the hematopoietic stem cell stage.96,97 
1.3 ii: The microenvironment in CLL 
In vitro CLL cell culturing studies have long implicated the microenvironment to play 
a crucial role in CLL survival. CLL cells in culture rapidly undergo apoptosis in the 
absence of vital survival factors which are now known to occupy niches within 
complex in-vivo micro-environmental networks.98-102 These networks involve active 
molecule cross-talk between CLL cells, accessory cells, activated T cells and a 
medley of soluble pro-survival chemokines and cytokines (Figure 1D). These 
molecules communicate through ligand-receptor and adhesion molecule interactions 
to activate autocrine and exocrine signaling in CLL cells.103-106 Overall, 
microenvironmental interactions of CLL cells seem to mainly mirror those of normal 
lymphocytes.103,107 However, certain distinct microenvironmental interactions 
controlling CLL migration do exist that are not seen in normal B cells.108 In addition 
to providing support to the CLL cell, the microenvironment is said to provide 
physical protection from cytotoxic drug damage, thus contributing to treatment 
resistance.109 CLL cell interactions within the bone marrow, peripheral blood and 
lymph node microenvironment are discussed below. 
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Figure 1D. The CLL cell microenvironment (Adapted from Burger et al 2009)110 
 
Bone marrow 
In the bone marrow, CLL cells come into contact with bone marrow stromal cells 
(BMSCs).100,101 In vitro, CLL cells co-cultured with BMSCs have been shown to live 
longer.100,101 This longevity is partially attributed to the interactions of BMSC CD54 
and CD106 integrins with CLL cell CD49d/CD11a or CD11b/CD18 integrins. This 
interaction is suggested to bring about protection from spontaneous apoptosis by 
increasing anti-apoptotic signals such as BCL2.100,111,112 Accompanying survival 
promoting events include the release of stromal cell chemokines such as, stromal cell 
derived factor 1 (SDF-1) otherwise known as CXCL12. SDF-1 production is 
constitutively produced by BM stromal cells in CLL patients.113 In response to SDF-1 
release, CLL cells migrate towards these growth supporting accessory cells via their 
highly expressed CXCLR4 receptors (Figure 1D).113,114 Once recruited, the stromal 
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cells adhere to CLL cells via VCAM-1 to VLA4 integrin interaction to subsequently 
activate anti-apoptosis pathways.100 
Peripheral Blood 
Unlike mononuclear cells in the peripheral blood of normal individuals, some cells in 
CLL patients regularly morph into large nurse like cells (NLCs) that adhere to 
leukemic cells in vitro.99 Similar to BMSCs, in-vitro co-culturing experiments have 
indicated the importance of NLC derived SDF-1 in the prevention of apoptosis 
through its interaction with CXCLR4 on CLL cells (Figure 1D). It is thought that 
perhaps NLCs help counteract apoptosis through the activation of MAP kinase 
ERK1/2 pathways that increase the expression of anti-apoptotic proteins like MCL-
1.115-117 
The lymph node 
The lymph node represents a specialized micro-environmental niche for CLL cells 
since it is the proposed main site of antigen encounter, BCR signaling and 
proliferation.105,118,119 In the past, CLL was solely considered to be an accumulative 
disease driven by defects in apoptosis. Nowadays it is seen as a disease afflicted by a 
concomitant increase in proliferation of the leukemic clone. Up to 1% of the CLL 
clone is now known to proliferate daily, within specialized pseudo-follicle structures 
known as proliferation centers (PCs).89,119 Large para-immunoblasts and pro-
lymphocytes within these structures highly express the proliferation marker Ki-67 
compared to smaller lymphocytes in the vicinity of the follicle.119 These large cells 
are also known to have constitutive activation of the NFĸB pathway, thus promoting 
cell proliferation through tight regulation of NFĸB target genes such as BCL-2 and 
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MCL-1.119-121 In support of these findings, CLL cells isolated from LNs have been 
recently shown to have an increased expression of active BCR signaling and 
proliferation genes relative to cells from the blood or bone marrow.118 
In PCs, subpopulations of T cells, stromal cells, macrophages and endothelial cells 
provide a cocktail of signaling mediators. Normally, the B cell receives survival 
signals via T cell CD40-CD40L stimulation. In CLL, increased numbers of T cells 
concentrate round PCs in response to B cell CCL22 release.119,122,123 Together, 
secretion of T cell derived cytokines like IL-4 and accessory cell chemokines such as 
SDF-1 support the expansion of CLL clones by up regulating anti-apoptotic 
SURVIVIN and BCL2 regulators.99,123 
LN derived CLL cells are known to harbor higher levels of CD38, compared to PB 
derived CLL cells.124,125 Additionally, in-vitro studies show an increase in CD38 
expression upon CLL activation126 thus proposing CD38 positivity as a characteristic 
of the CLL cell-LN microenvironment interaction. CD38+ cells have been reported to 
interact with CD31 on stromal cells to promote CLL proliferation.127,128 In fact, 
CD38+ cells are said to proliferate ~2X as fast as CD38- cells in vivo.129 It is thought 
that CD38+ cells gain an enhanced migratory ability to home to favourable 
microenvironments due to an elevated responsiveness to the CD31 stromal ligand. 
Alternatively, given the strong association between CD38 positivity and increased 
CD31+ vascularisation in lymph nodes, it is further proposed that the 
microenvironment itself may induce CD38 expression.130,131 Given its function as an 
accessory BCR signaling molecule, it is suggested that CD38+ cells can strongly 
transduce signals from their BCR, unlike their negative counterparts.132,133 Altogether 
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these circumstances have culminated to suggest that CD38+ cells constitute the 
fraction of cells primed to proliferate in CLL. 
1.3 iii: Evidence of antigen(s) involvement in CLL pathogenesis 
 
Currently, the exact role of antigen(s) in CLL leukemogenesis is unknown. 
Deciphering whether antigen(s) play vital a part in CLL initiation by providing a 
proliferative stress or whether they contribute to CLL progression through chronic 
stimulation of the CLL clone is an active area of current research. Despite these 
uncertainties pertaining to time of antigen engagement in CLL pathogenesis, a 
plethora of circumstantial evidence supports the involvement antigen at some stage of 
CLL development. This evidence stems from the finding that compared to the normal 
repertoire; CLL shows a biased use of certain IGHV genes, namely IGHV1-69, 
IGHV3-7, IGHV3-23, IGHV3-21 and IGHV4-34.3,134,135 Additionally, IG sequence 
analysis has described the presence of multiple CLL subsets with closely homologous 
or stereotyped BCRs.4-6,134,136-138 More specifically, these stereotyped subsets are 
characterised by an amino acid identity of ≥60% in the heavy chain CDR3 and 
restricted usage of similar IGHV-D-J genes and light-chain genes. In fact, later 
reports have evidenced that ~30% of CLL patients belong to subsets (>100 defined 
today) carrying ‘stereotyped’ CDR3 sequences on their heavy and light chains.5,6 
Considering the likelihood of finding two B cell clones with identical BCRs is almost 
negligible, these findings are highly suggestive of antigen(s) involvement in 
leukemogenesis.4-6,136,137 
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1.3 iv: The molecular nature of antigen(s) in CLL 
 
The specific nature of the antigen(s) involved in CLL is largely unknown. It is 
suspected that foreign antigens,139 auto-antigens94 and super-antigens6 or 
combinations thereof play a role in CLL leukemogenesis. The reactivity of CLL cells 
to antigen stimulation has been shown to differ depending on the mutational status of 
the BCR. For instance, unmutated BCRs have been shown to be polyreactive against 
such molecules as bacterial lipo-polysaccharides (LPS). Moreover, unmutated BCRs 
have demonstrated autoreactivity against insulin and DNA molecules.139,140 In 
contrast, mutated BCRs appear to loose their polyreactivity upon acquiring mutations 
through SHM.139 
CLL BCRs including several stereotyped cases, have demonstrated homology to anti-
DNA, anti-rheumatoid factor, and anti-cardiolipin auto-antibodies.5 Moreover, BCR-
stereotyped CLL cells have been shown to bind intracellular autoantigen such as 
cytoskeletal proteins vimentin and oxidised low density lipoproteins.141,142 More 
recently, auto-antigen in the form of antigenic motifs on apoptotic blebs from dead 
cells have been implicated in CLL leukemogenesis. It is thought that the BCR can 
recognise these motifs leading to self stimulation and expansion of the CLL 
clone.141,142 For example, unmutated CLL monoclonal antibodies have been shown to 
specifically bind non-muscle myosin heavy chain IIA (MYHIIA9) exposed apoptotic 
cells (MEACS). This event has been particularly evident in ‘subset #6’ patients 
expressing IGHV1-69/IGHD3-16/J3 genes.143 In light of the latter finding, it is has 
been suggested that CLL clones may arise from dual functional B cells that maintain 
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their ability as scavengers of apoptotic residues, whilst sustaining their ability to bind 
conserved bacterial cell motifs.142,144 
Interestingly, self antigens have been noted to bind certain IGHV3 and IGHV4 BCRs 
outside of the CDR3 region, instead binding to IG FWRs. Similarly, bacterial super-
antigens have been shown to bind FWR1, FWR3 and CDR2 regions of some IGHV3 
BCRs.139,145,146 Details of these proposed superantigens are discussed below in 
relation to the IGHV gene family in which they are suspected to have a role. 
1.4: IGHV3-21 and IGHV4-34 CLL subgroups: IG sequences, 
antigens and clinical implications 
1.4 i: IGHV3-21 utilising patients 
IGHV3-21 patients have been shown to demonstrate a poor clinical outcome and 
aggressive disease regardless of their IGHV mutation status.4,135,137,147 In recent years, 
studies of IGHV3-21 CLL have reported an abundance of evidence linking antigen 
involvement to IGHV3-21 pathogenesis.4,6,135,137,148 For instance, approximately 50% 
of CLL patients using the IGHV3-21 gene demonstrate stereotyped BCRs and these 
are denoted as subset #2 patients. More specifically, subset #2 IGHV3-21 patients 
carry stereotyped BCRs consisting of a conserved 9 amino acid long HCDR3 
sequence (Figure 1E).137,148-150 In a large proportion of cases, the amino acid sequence 
of these stereotyped HCDR3 regions are identical (ARDANGMDV). However, in 
some cases sequences may differ merely by 1-3 amino acids at different positions. 
Furthermore, in the majority of subset #2 cases, it is not possible to assign any D gene 
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usage.137,147,148,150 Interestingly, IGHV3-21 stereotyped patients show restricted 
expression of the IGLV3-21 gene.137,147,148 Altogether, these findings indicate the 
recognition of a common antigen in IGHV3-21 subset #2 cases.4-6,137,147,148 
 
 
 
 
Figure 1E. A representation characterising IGHV3-21 stereotyped and non-stereotyped 
BCRs 
 
Non-stereotyped IGHV3-21 (non-subset #2) patients have a heterogeneous CDR3 
and light chain gene usage (Figure 1E). Both stereotyped and non-stereotyped BCRs 
have been reported to share an equally poor overall survival similar to that displayed 
by other IGHV unmutated cases (see prognostic markers section). Nevertheless, 
IGHV3-21 stereotypy has also been suggested to influence clinical behaviour. For 
instance, patients carrying stereotyped CDR3s are proposed to have a more 
progressive disease compared to non-stereotyped patients.5,149 Supporting this 
proposal is the finding that IGHV3-21 patients with homologous HCDR3s more 
frequently express high levels of the poor prognostic markers CD38 and 
ZAP70.5,147,150 
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IGHV3-21 sequences are predominantly border-line mutated. This finding can be 
partially explained by the under-targeting of SHM across all regions of IGHV3-21 
sequences compared to other IGHV3 subgroup genes.6 Interestingly, IGHV3-21 
subset #2 patients have been shown to have lower targeting of mutations across all IG 
regions except the HCDR2 compared to non-subset 2 IGHV3-21 sequences. That 
said, several recurrent amino acid changes have been observed among subset #2 
cases. Remarkably, a serine deletion at HCDR2 codon 59 is commonly detected in 
stereotyped IGHV3-21 CLL sequences.6 This deletion appears to be both a CLL and 
subset biased mutation. The finding of specific recurrent mutations in IGHV3-21 
CLL further strengthens the role of antigen selection in CLL. 
Interestingly, IGHV3-21 patients and in particular stereotyped patients, showed a 
strong tendency to the retain germline configuration in the binding motif for 
Staphylococcal protein A, a suspected superantigen in CLL.6 However, the biologic 
and clinical implications of this finding (if any) remain unknown. Additionally, 
mutated IGHV3-21 subset #2 cases have been shown to bind the intracellular auto-
antigen cofilin-1, an actin binding protein found localise with molecular complexes 
on the cell surface at apoptosis.142 
Finally, a geographic bias has been attributed to this poor prognostic IGHV3-21 gene. 
For instance, Scandinavia has demonstrated the highest IGHV3-21 gene frequency 
(10-13%)4,135,137,150 compared to other Southern European countries and North 
America (~3-4%).5,151,152 These findings suggest that aside from geographical bias, 
differences in ethnicity and/or environment may account for the varying frequency of 
the IGHV3-21 gene seen globally. Nevertheless, it is also possible that biases in 
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sample selection can contribute to the varying IGHV3-21 gene frequencies detected 
around the globe.4,5,135,137,147,149-155 
1.4 ii: IGHV4-34 utilising patients 
IGHV4-34 gene usage is seen in approximately 8-10% of CLL patients. Two CLL 
subsets carrying stereotyped IGHV4-34 BCRs namely subset #4 and subset #16 have 
been described in CLL. Subset #4 is the most common stereotyped subset occurring 
at an overall frequency of ~1%. This subset is characterised by a 20 amino acid long 
CDR3 sequence and restricted usage of the IGKV2-30 light chain (Figure 1F). 
Furthermore, these patients almost exclusively carry IGHV mutated genes. 
Remarkably, these restricted biological features are associated with an indolent 
disease course compared to non-stereotyped IGHV4-34 CLL patients displaying non-
restricted IG features (Figure 1F).5,6 The indolent disease course noted for these 
patients, may in part be explained by the fact that these cases are associated with low 
expression of the poor prognostic CD38 marker. Interestingly, subset #4 patients have 
a low median age at diagnosis.5 Moreover, these patients demonstrate a potential 
association with persistent infection by common herpes viruses such as EBV and 
CMV.156 Recently, subset #4 cases have been shown to display extensive intraclonal 
diversification suggesting a role of ongoing active antigen stimulation in these 
cases.157 
 
The second IGHV4-34 stereotyped subset, subset #16 is present at an overall 
frequency of 0.3%. This subset is characterised by mutated IGHV genes, a restricted 
IGKV3-20 light chain usage and a 24 amino acid long homologous CDR3 sequence 
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IGHV4-34 
IGKV3-20  
Subset #4 
IGHV4-34 
IGKV2-30  
Homogenous CDR3  
~ 20 aa 
Subset #16 
Homogenous CDR3 
~24 aa  
Non-subset 
#4/16 
Heterogenous 
CDR3  
(Figure 1F). However, as this subset is not commonly encountered little is known 
about the clinical outcome for these patients.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1F. A representation characterising IGHV4-34 stereotyped and non-stereotyped 
BCRs 
 
In the germline state IGHV4-34 BCRs appear to be inherently autoreactive and may 
bind to auto-antigens. However, since IG sequencing studies have revealed IGHV4-
34 BCRs to be mainly mutated,6 it has been suggested that through SHM, IGHV4-34 
BCRs can alleviate their auto-reactivity.158 More specifically, stereotyped IGHV4-34 
cases demonstrate stereotyped amino acid sequence changes at their IGHV genes and 
these changes are largely subset biased. Stereotyped IGHV4-34 subsets #4 and #16 
have distinctive SHM distribution patterns in their HCDRs and HFRs compared to 
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their non-stereotyped counterparts. For instance, subsets #4 and #16 carrying basic 
lysine residues within their HCDR3 regions also incur stereotyped mutations in the 
HCDR1 region resulting in the introduction of negatively charged residues. The latter 
mutations are said to eliminate the potential DNA binding properties given by the 
positively charged HCDR3 region. Furthermore, it is noted that in stereotyped 
IGHV4-34 subsets the HFR1 motif conferring anti I/i reactivity is rather conserved 
compared to non-subset cases. Hence, these subsets hold the potential to bind the I/i 
blood group antigen or the B cell isoform of CD45 containing the N-
acetyllactosamine antigenic determinant. Hence, through SHM, IGHV4-34 utilising 
B cells lose their auto-reactivity transitioning to a more safe state so that they can 
persist within the functional IG repertoire.6,94 
In summary, the proposed stepwise model of CLL leukemogenesis suggests that the 
survival of the preleukemic clone depends on the interaction of CLL cells with the 
pro-survival microenvironment. Antigen(s) residing in this microevironment are 
thought to provide transient or chronic stimulation to the CLL clone. Under this 
model, antigen stimulation, aberrant genetic alterations and epimutations work 
together in a stepwise fashion to create a thriving CLL clone. Transforming and 
progressive events may occur at currently unknown discrete B cell developmental 
stages or randomly depending on the type, efficiency and potency of promotional 
microenvironmental signals. A summary of the genetic and epigenetic alterations 
seen in CLL will be described within the following sections. 
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1.5: Prognostic markers in CLL 
1.5 i: IGHV gene mutational status 
In 1999, two independent studies demonstrated that the IGHV mutational status could 
categorise CLL into divergent clinical subgroups. Remarkably, the IGHV mutation 
status allowed the subdivision of CLL into two disease entities where patients with 
unmutated IGHV genes were shown to experience an inferior prognosis while, 
patients with mutated IGHV genes demonstrated a superior prognosis.2,3 More 
specifically, patients with IGHV unmutated genes have a more aggressive condition, 
including evidence of advanced progressive disease, atypical peripheral blood cell 
morphology, adverse cytogenetic features, clonal evolution, and resistance to therapy, 
than those with mutated IGHV genes.2,3 As mentioned, an exception to this rule is the 
presence of the IGHV3-21 gene (see the IGHV3-21 utilising patients section). 
Today it is widely accepted that a 98% identity cut-off is best at making the clinically 
relevant distinction between mutated and unmutated CLL. CLL patients who carry 
IGHV genes with ≥98% identity to germline are considered unmutated whereas 
patients with <98% identity to germline are denoted as mutated.2,3,159,160 Nevertheless, 
applying this arbitrary mathematical cut-off to a biological event must be interpreted 
with caution, particularly when dealing with borderline cases. Despite the advantages 
of this robust prognostic marker, the methods used to obtain IGHV gene sequences 
can be laborious, thus the search for more accessible prognostic markers conducive to 
routine procedures are well sought after. 
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1.5 ii: Protein based markers: CD38 and ZAP70 expression 
CD38 expression was the first prognostic factor found to correlate with IGHV 
mutational status, where high expression was shown to be associated with unmutated 
genes and a poor prognosis.2,124,159,161 However, it has been evidenced that this 
relationship does not always hold true.159,162,163 Another issue preventing the use of 
CD38 expression as a substitute marker for mutational status is the lack of a 
definitive threshold delineating what percentage of the CLL clone should possess 
elevated CD38 expression in order to assign CD38 positivity.161,164 Moreover, CD38 
has been reported to vary over time.124,162 Nevertheless, CD38 expression is 
considered an independent prognostic marker, albeit not the strongest.165 
Similarly, ZAP70 expression shows a good correlation to IGHV mutational status. In 
general, the majority of mutated cases are shown to be ZAP70 negative, whereas 
unmutated cases are mainly shown to be positive.166 Nevertheless, Rassenti et al 
demonstrate that approximately 23% of patients show discrepant results that do not 
correlate with mutational status.167 Discordant cases may frequently present with 
other poor prognostic features such as del(17p), del(11q) and/or IGHV3-21 
expression. For instance, 17p and 11q deleted patients have been found to have a low 
expression whereas IGHV3-21 patients have been shown to have a high 
expression.168 Interestingly, Rassenti et al have further shown ZAP70 expression to 
be a better predictor of time to progression compared to IGHV mutational status. 
Another advantage of ZAP70 measurement is the fact that ZAP-70 levels also appear 
to remain stable over time.167 
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ZAP70 measurement holds many advantages in that it can be easily measured by 
readily available methods such as flow cytometry at the protein level and RQ-PCR at 
the gene level 166,169 ZAP70 is expressed by other immune cells such as natural killer 
(NK) and T cells which may influence ZAP70 expression analysis. Therefore, it is 
required that CLL tumour B cells be purified away from such cells prior to ZAP70 
expression analysis. Hence, the inconvenience of having to perform cell purification 
prior to analysis makes measurement of ZAP70 expression non conducive for use in 
clinical routine. 
 
1.5 iii: RNA based markers: LPL and CLLU1 expression 
Today, Lipoprotein lipase (LPL) gene expression serves as an independent prognostic 
marker in CLL.170 Over a decade ago, gene expression studies identified LPL to be 
differentially expressed in IGHV mutated and unmutated CLL.95,171 Although not 
highly expressed in CLL, LPL expression is higher in IGHV unmutated patients 
relative to IGHV mutated CLL patients.170 Expression further correlates with other 
negative prognosticators such as high CD38, ZAP-70 expression and poor genetic 
alterations.172 Predictive of a shorter treatment free survival and in most cases a 
shorter overall survival, LPL expression in some instances has been deemed as a 
superior independent prognosticator compared to IGHV mutational status.170,173 
Moreover, its prognostic value is maintained independently of clinical stage.172-175 
Very low LPL expression in normal peripheral blood mononuclear cells 
(PBMCs)174,176 permits the use of non-sorted PBMCs from CLL patients for analysis. 
Altogether, quantification of LPL expression by RQ-PCR may offer a cheaper, less 
labour intensive method to identify prognostic subgroups of CLL patients. 
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Differential display screening first identified CLL upregulated gene 1 (CLLU1) to be 
differentially expressed in CLL. CLLU1 is highly expressed in IGHV unmutated 
patients relative to mutated patients177,178 and is associated with other poor risk 
characteristics namely advanced clinical stage, poor cytogenetics and high CD38 and 
ZAP70 expression.173,178,179 Like LPL, high CLLU1 expression correlates to a shorter 
overall survival and treatment free survival.173,178,180 Recently, the value of CLLU1 
expression in IGHV mutated patients has revealed important prognostic information, 
indicating those IGHV mutated patients with high CLLU1 expression to have a worse 
prognosis relative to mutated patients with low expression.179 Additionally, CLLU1 
expression appears to be exclusive to CLL cells and is stable over time.180 Hence, 
determination of CLLU1 expression levels can be used as a reliable indicator of 
tumour burden and is suggested to complement currently used techniques for minimal 
residual disease (MRD) monitoring in CLL patients post therapy.181 
1.5 iv: Genomic alterations 
 
CLL is not defined by a single recurrent genomic alteration but rather by genomic 
instability that frequently culminates into chromosomal aberrations which are present 
in up to 80% of patients. Today, fluorescent in-situ hybridization (FISH) techniques 
are implemented to detect the most common chromosomal alterations namely 
del(13q), del(11q), del(17p) and trisomy 12, which are of important prognostic 
significance in CLL (Table 1A).7 
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Deletion 13q 
Deletion at chromosome 13q14 is the most frequently encountered alteration 
affecting up to 55-60% of CLL patients (Table 1A).7 Deletion of 13q most often 
occurs as the sole alteration and is associated with a favourable prognosis and 
indolent disease course.7 However, the prognostic significance of mono-allelic versus 
bi-allelic deletions of 13q still remains controversial. Recently, a study revealed that a 
similar time to initial treatment and overall survival was attained in both mono- and 
bi-allelic del(13q) CLL patient groups.182 However, conflicting reports have 
suggested that bi-allelic disease is associated with a tendency for better overall 
survival compared to mono-allelic disease.183 That said, a study by Chena et al184 has 
shown bi-allelic del(13q) patients to have a shorter treatment free survival relative to 
heterozygous patients. Moreover, copy number neutral loss of heterozygosity (CNN-
LOH) events involving the loss of one allele and the subsequent duplication of the 
alternative allele have been reported in CLL.183 Interestingly, these events have been 
reported on 13q, particularly in patients showing bi-allelic deletions of 13q.183 These 
observations suggest that the recurrence of CNN-LOH at chromosome 13 is an 
important mechanism in CLL biology. 
It is further argued that detection of del(13q) is not fully sufficient to define a CLL 
with a good prognosis. For instance, the size of the clone carrying this alteration may 
influence the disease course. Recent reports reveal that patients harboring a higher 
percentage of del(13q) cells among their CLL clone have a worse clinical outcome 
compared to those with a lesser percentage of cells.182,185 Further, evidence is given 
by recent SNP profiling studies demonstrating the heterogeneity of 13q deletions in 
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terms of alteration size, the genes they cover and the location of their breakpoints. For 
instance, in most 13q deletion cases a minimally deleted region (MDR) covering 
DLEU1, DLEU2, miRNA-15a and miRNA-16-1 genes is noted.186-188 Interestingly, a 
study by Ouillette et al found that patients with del(13q) covering the MDR and the 
RB gene positioned beyond the MDR region were associated with a higher Rai stage 
compared to del(13q) patients not including the RB gene. Moreover, patients with 
deletions covering the MDR in addition to the RB gene were more likely to be 
treated. Hence, it appears that genes outside of the MDR play key roles in hampering 
patient outcome.189 
In del(13q) CLL, it is suspected that deregulation of miRNA-15a/miRNA-16-1 and 
hence, deregulation of its downstream target the anti-apoptotic BCL2 gene, may 
confer a selective cumulative advantage.186 The roles of DLEU1 and 2 are less clear, 
however it is known that DLEU2 expression provides the primary transcript for 
production of miRNA-15a/miRNA-16-1.190 Like miRNA-15a/miRNA-16-1, the DLEU7 
gene is also positioned within the MDR in 13q deleted patients. DLEU7 plays a key 
function as a potent NFkB inhibitor by interacting with members of the tumour 
necrosis factor (TNF) receptor family.191 Moreover, studies on lung cancer cell lines 
have shown DLEU7 expression to result in an increase in apoptosis.191 These 
observations suggest that loss of DLEU7 may work in an additive manner with the 
loss of miRNA-15a/miRNA-16-1 to augment the pathogenesis of del(13q) CLL.191 
A recent mouse study has provided in vivo evidence suggesting that the 
DLEU2/miRNA-15a/miRNA-16-1 locus controls B cell expansion by modulating 
proliferation rather than affecting survival via the anti-apoptotic BCL2 gene.190 This 
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study suggests that the function of this locus may be to tightly regulate cell cycle 
entry in response to antigen. This is supported by the observation that 
DLEU2/miRNA-15a/miRNA-16-1 expression was down-regulated in proliferating B 
cells within germinal centers, thus establishing a tumor suppressor role for this locus. 
Moreover, deletion of the DLEU2/miR-15a/16-1 cluster in mice was shown to cause 
the development of indolent B cell-autonomous, clonal lymphoproliferative disorders 
akin to the spectrum of CLL-associated phenotypes observed in humans. In addition, 
this study demonstrated that miRNA-15a/miRNA16-1-deletion in human and mouse 
leads to an accelerated B cell lymphoproliferative state that arises through modulating 
the expression of genes controlling cell-cycle progression.190 
Deletion 11q 
Deletion of 11q is the second most common alteration in CLL (12-18%) and is 
associated with an aggressive disease course and a poor clinical outcome (Table 1A).7 
These patients are often characterized with abdominal or mediastinal 
lymphadenopathy.192 Molecular characterization of del(11q) has identified a 
minimally deleted region of 2-3Mb that includes the ATM gene. In the majority of 
cases, ATM a tumour suppressor gene is considered the most likely candidate gene in 
del(11q) CLL, since it is known to play a vital role in activating p53 and augmenting 
the DNA damage response. Due to the integral role of ATM in maintaining genome 
stability, mutation of ATM is strongly suggested to be involved in CLL 
pathogenesis.192-194 Furthermore, approximately one third of 11q deleted CLL 
patients display a somatic or germline ATM gene mutation.195,196  
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Similar to del(13q) alterations, a marked complexity in the size and structure of 11q 
deletions has been shown. For instance, a deletion of 11q can be discontinuous which 
is indicative of complex genomic events taking place.183,197 In some cases 11q 
deletions do not cover the ATM gene thus indicating the importance of alternative 
genes in the critical region such as RDX. In other instances, genes outside of this 
region such as the MLL gene may play a role in certain 11q deleted CLL cases.192,194 
Recently, SNP analysis has demonstrated a MDR of 0.68Mbp at 11q22.3 
encompassing the following genes, CUL5, RAB39, ACAT1, NPAT and KDELC.198 
However, a more recent study describes a new MDR for 11q22.3 excluding the 
RAB39 gene. 199  
 
Deletion of miR-34b/miR-34c is also thought to play a role in del(11q) CLL 
pathogenesis. Given the important function of micro RNA in guiding cell 
proliferation and survival it is interesting to speculate that loss of miR-34b/miR-34c 
may contribute to the aggressive disease state seen in del(11q) patients. In fact one 
study demonstrates miR-34b-5p to target the TCL1 oncogene which may contribute to 
TCL1 overexpression seen in CLL.200 Surprisingly, a conserved gene in the critical 
region of 11q22-23 called ARHGAP20 is shown to be substantially up regulated in 
11q deleted cases relative to patients to with no genomic alterations and trisomy 12 
patients. Interestingly, 13q deleted patients also have a higher expression of this 
gene.201 This finding supports a functional link between 11q and 13q deletions in 
CLL. This notion is further endorsed by the finding that both MDRs in 13q and 11q 
are syntenic to a single region in the zebra fish on chromosome 9. 202 
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Trisomy 12 
Today trisomy 12 is considered the third most common genetic alteration in CLL 
occurring in 11-16% of patients (Table 1A).7 Trisomy 12 is caused by the duplication 
of one of its chromosome pairs and is associated with an intermediate survival and 
shorter time to treatment.7,203 Little is known of the pathogenesis behind trisomy 12 
CLL, however, chromosome banding studies have identified a partial trisomy 12q13-
q15 in a minority of patients covering the MDM2 gene, a known gene deregulated in 
CLL and a negative regulator of p53.204-207 Another candidate gene known to be up 
regulated in CLL is the disease specific CLLU1 gene located at 12q22, however 
CLLU1 expression was not found to relate to trisomy 12.177 Nevertheless, new gene 
expression studies have provided further insight into trisomy 12 CLL pathogenesis. 
Recently, four genes have been shown to be significantly associated with trisomy 12 
CLL, including overexpression of the HIP1R gene at 12q24 and the MYF6 gene at 
12q21. In contrast, the P2RY14 gene at 3q21-q25 and CD200 at 3q12-q13 were 
shown to be under-expressed in trisomy 12 patients.208 
Deletion 17p 
Deletion of 17p, covering the TP53 gene, occurs in up to 10% of CLL patients and is 
associated with a particularly poor survival and short time to treatment (Table 1A).7 
Moreover, deletion of 17p is commonly observed to co-exist with other unfavorable 
prognostic markers such as unmutated IGHV genes, high ZAP70 and CD38 
expression.159 Additionally, del(17p) patients experience chemo-refractoriness as 
chemotherapeutic reagents often work by inducing apoptosis or impeding the cell 
cycle via the p53 pathway.209 Nevertheless, reagents which utilize p53 independent 
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mechanisms such as alemtuzumab, an anti-CD52 monoclonal antibody can be 
implemented in these cases.28 Recent studies have shown that the majority of 17p 
deleted patients present with TP53 mutations on their other allele, however it was 
also shown that a subset of CLL patients carry TP53 mutation without a deletion of 
17p (Table 1A).210-212 In fact, patients solely carrying a 17p deletion or TP53 
mutation alone have an equally poor overall survival similar to those patients carrying 
both del(17p) and TP53 mutation. Thus, TP53 mutational status is an independent 
prognostic indicator that is important for steering treatment choices.210-213 
Deletion 6q 
Today, approximately 6-7% of patients acquire del(6q) (Table 1A).214,215 However, it 
is considered a progression marker as it is mainly detected in CLL patients at follow 
up.216 Deletions are most frequently encountered at 6q21, however deletions at 6q27 
have also been detected.214-218 No definitive tumour suppressor genes have been 
accounted for in del(6q) CLL pathogenesis. The presence of del(6q) has been 
associated with an increased white blood cell count and in some cases a more 
extensive lymphadenopathy. Despite these associations, it does not appear to be a 
negative prognostic indicator in CLL. That said, some studies have associated 6q 
deletions with a shorter treatment free survival.215,219,220 
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Table 1A. Summary of Genomic alterations in CLL. 
 
 
Translocations in CLL 
In the past, cumbersome classical cytogenetic methods used to detect translocations 
in CLL were often unsuccessful (see the Genomic profiling technologies section). 
Hence, the frequency of CLL translocations was grossly under estimatated at this 
time. Today, new and improved cytogenetic analysis has allowed the detection of 
translocations in up to 30% of CLL patients, however these are largely non-recurrent 
events.203,221 The presence of balanced and unbalanced translocations are linked to an 
unfavourable clinical outcome in CLL.221 Interestingly, recurring breakpoints in CLL 
translocations are shown to cluster in regions affected in other lymphomas, such as 
1(q21q25), 1(p32p36), 2(p11p13), 6(p11p12), 6(p21p25), 13q14, 14q32, and 
18q21.222 These regions are suspected to contain genes involved in CLL 
leukemogenesis. For instance the t(14;19)(q32;q13) translocation involves the 
juxtaposition of the transcriptional co-activator BCL3 gene to the IGH locus causing 
an increase in BCL3 expression.223,224 
Alteration Del(17p) 
 
TP53  
mutation 
del(11q) Trisomy 12 del(13q) Deletion 6q 
 
Frequency 
 
5-10% 
 
1-5% 
 
12-18% 
 
11-16% 
 
55% 
 
6-7% 
 
Candidate gene(s) 
 
TP53 
 
TP53 
 
ATM 
 
unknown 
 
miR-15/16 
 
unknown 
 
Clinical outcome 
 
poor 
 
poor 
 
poor 
 
intermediate 
 
good 
 
progression 
 
Use in clinical 
routine 
 
yes 
 
no 
 
yes 
 
yes 
 
yes 
 
no 
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Genomic complexity 
Recently, a correlation between genetic complexity and clinical outcome has been 
described in CLL.225 For instance, a recent SNP study showed CLL patients carrying 
more than two alterations to have a poorer overall survival.225 Similarly, patients 
carrying a higher number of larger sized alterations have been associated with a 
worse clinical outcome compared to those with smaller alterations.183 Additionally, 
the genomes of patients carrying deletions of 11q and 17p are shown to be more 
complex. For instance, a recent study demonstrated that patients with four or more 
alterations greater than 5Mbs carried del(17p) or del(11q). Hence, due to the loss of 
vital genes integral to genome stability, the genomes of 11q and particularly 17p 
deleted patients are more complex and thus more likely to acquire further alterations 
compared to other CLL patients.183 
 
Novel alterations 
Reports have indicated del(14q) as a recurrent alteration in CLL occurring in ~1.5% 
of patients.226 It is has been shown that this aberration most often occurs in IGHV 
unmutated patients.226 Furthermore, del(14q) patients were shown to have a high 
occurance of trisomy 12. Deletion of 14q was associated with an intermediate 
survival and shorter time to treatment although low sample numbers were 
investigated. Deletions of 14q are heterogeneous in size; however, recurrent 
breakpoints have been documented.226 Due to the frequency of these alterations and 
their association with disease outcome, it is widely debated whether or not to include 
deletions of 14q to the established FISH panel for detection of known recurrent 
alterations in CLL. 
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Through the use of new microarray studies, some novel alterations such as gain of 2p, 
gain of 8q and loss of 4p, 8p and 22q have been identified,183,227-229 however no 
consensus exists regarding the frequency of these novel alterations. This is likely due 
to discrepancies in the array platforms employed and the study populations 
investigated. Interestingly, gain of 2p covering the MYCN oncogene was recently 
found in up to 28% of untreated Binet stage B/C patients.230 These patients also 
experienced an increased MYCN mRNA expression, suggesting MYCN to have a 
pathogenic role in these CLL cases.230 Additionally, a recent SNP-array study showed 
this alteration to occur frequently in del(11q) patients.183 In patients with a loss at 
chromosome 22q, the PRAME gene has been implicated as the candidate gene of 
interest.228 Finally, dic(17;18)(p11.2;p11.2) a dicentric chromosome alteration has 
been described as a novel recurring abnormality in CLL. This aberration is associated 
with a complex karyotype, progressive disease, unmutated IGHV genes and an early 
age at diagnosis relative to other CLL patients.231 
Today, a small percentage of trisomy 12 patients 1.6-5% are known to carry a 
coexisting trisomy on chromosome 19.232-234 More recent studies have shown this 
genetic profile to occur exclusively in isotype switched sIg positive CLL. 
Interestingly, this profile has been associated with the use of IGHV mutated genes 
and high CD38 expression. Furthermore, it has recently been discovered that these 
cases are often found to carry trisomy 18.235 Notably, trisomy 12 has been reported to 
be associated with CLL patients expressing IgG-positive stereotyped unmutated 
IGHV4-39/IGKV1-39 (1D-39) BCRs.236 In some instances, these cases have been 
shown to be associated with the t(14;19)(q32;q13) translocation. As mentioned above 
(in the translocations in CLL section), t(14;19)(q32;q13) causes the BCL-3 proto-
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oncogene to become juxtaposed next to the IGH locus resulting in overexpression of 
the BCL-3 protein and deregulation of NF-κB.177,223,237 
With the advent of whole genome sequencing technologies a number of novel 
mutations have recently been discovered in CLL. Studies have identified repeated 
mutations in XPO1, a nuclear transport factor gene in ~2.4% of patients238,239 and 
NOTCH1, a ligand activated transcription factor gene in ~12.2% of CLL cases. 
NOTCH1 mutations are more frequently found in IGHV-unmutated/ZAP70+ cases 
compared to IGHV-mutated/ZAP70- patients. More specifically, NOTCH1 mutations 
are reported to occur in 18-20% of IGHV-unmutated/ZAP70+ patients and 4-7% of 
mutated/ZAP70 cases.239,240 In contrast, a frequency of 4% in IGHV-
unmutated/ZAP70+ and 1.5% in mutated/ZAP70 cases has also been reported. 
NOTCH1 mutations in CLL have been frequently found to occur in trisomy 12 
patients. Altogether, these findings suggest NOTCH1 activation to play a role in 
IGHV-unmutated/ZAP70+ trisomy 12 CLL.238 In addition to these genes, recurrent 
mutations of MYD88 and SF3B1 have been identified in 10% and 15% of CLL cases 
respectively. Interestingly, SF3B1 mutations are shown to occur in CLL patiens 
carrying deletion 11q.241 
1.6: Genomic profiling technologies 
Karyotyping ascertains gross chromosomal features such as chromosome number, 
size and structure. Conventional cytogenetic staining techniques such as G, Q and R-
banding pinpoint the chromosomal regions affected by genomic alterations, however, 
only large alterations (approximately from 5-10 Mb) across chromosome metaphase 
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spreads are analysed.242 This method requires cumbersome cell culturing which has 
often lead to a low percentage of successful karyotypes for CLL cells, given their 
inherent inability to survive and proliferate ex-vivo.243,244 However, today the use of 
growth stimulants such as CpG oligonucleotides, IL-2 and CD40L, have allowed 
better detection rates in CLL.243,244 
Today, in clinical practice, interphase FISH is instead the gold standard method of 
choice for CLL, since it has the ability to detect smaller DNA target sequences (probe 
size starting at 100-1000bp) without cumbersome culturing methods.245-247 FISH 
involves the hybridization of a panel of fluorescently labelled region specific probes 
to complementary DNA sequences at specific chromosomal regions. In CLL, 
interphase FISH can detect clinically relevant and recurrent lesions in up to 80% of 
CLL patients.7 The advantage of FISH relies on its ability to detect alterations even in 
samples with a low percentage of tumour cells. Other advantages include its capacity 
to detect homo- and heterozygous deletions and gains, as well as complex 
chromosomal translocations and rearrangements. That said, FISH is limited in its 
ability to detect aberrations that lie outside of the probe specific regions, making 
global screening difficult. Techniques such as spectral karyotyping and multiplex 
FISH simultaneously employ multiple probes sets in order to asses all chromosomes. 
However, these technologies are costly and labour intensive and in some instances 
limited by difficulties in probe design to certain chromosomal regions.245,247,248 
Unlike FISH, comparative genomic hybridisation (CGH) has the ability to readily 
examine the entire genome for alterations (approximately 5-10 Mbp in size). CGH 
involves the quantitative hybridization of differentially labeled normal and tumour 
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DNA to normal metaphase chromosomes. On the other hand, CGH has a low 
sensitivity, requiring a high percentage of cells to have a particular alteration in order 
to be detectable. Furthermore, such alterations as inversions and translocations can 
not be identified.249 
Today, the need for genome wide, high resolution scanning has culminated in the 
development of array technologies and sequencing platforms allowing broader 
characterization of known alterations and novel smaller genetic lesions contributing 
to complexity. Array-comparative genomic hybridization (aCGH) and single 
nucleotide polymorphism (SNP) array technologies investigate global genomic events 
with the exception of repetitive regions, without the requirement of cumbersome 
metaphase chromosome preparations. Using aCGH, copy number alterations (CNAs) 
at a level of <100 kb can be detected. 
In general, aCGH utilises the same principals as those of conventional CGH except 
that instead of employing metaphase chromosomes as targets, thousands of short 
DNA probes representing the genome are arrayed onto a chip.250 aCGH designed 
using bacterial artificial chromosomes (BAC) tend to hold a lower power of 
resolution251 compared to aCGH oligo-nucleotide arrays.252 Oligo aCGH permit a 
higher resolution to BAC arrays since a higher number of probes made up of 60-mer 
oligonucleotides are hybridised to the chip. Although a reliable method, aCGH is 
limited by its inability to detect CNN-LOH events. In contrast, SNP array platforms 
allow for the simultaneous detection of CNN-LOH events and CNAs at high 
resolution down to ~10-25kb in size depending on the array.253 
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SNP arrays are constructed using 25-30-mer oligonucleotide probes containing 
specific SNPs. Each SNP position across the genome possesses two allelic variants 
on the array, SNP A and SNP B. Today up to 106 probes can be spotted on the array. 
After hybridising the sample of interest to the array, SNP copy number is determined 
from the fluorescent signals arising from SNP A and B alleles. Normalising the SNP 
data to a previously analysed healthy individual reference set determines 
sample/reference ratios indicating the presence of chromosome alterations. One crux 
of such SNP and array-CGH technologies is that they do not detect alterations that 
occur in a low percentage of tumour cells.254 Failure to detect alterations also depends 
on the platform and the algorithm used. For instance, some algorithms do not tolerate 
normal cell contamination >20%, whereas some algorithms are adjusted to account 
for normal cell interference.254 
In the case of CLL, alternative optimization measures such as B cell enrichment 
techniques help resolve the issue of normal cell contamination and low tumour 
percentage.254 Recently, the Affymetrix 250K SNP array technology used in this 
thesis, have been correlated to FISH analysis in CLL patients. Remarkably, this array 
showed a 98.5% correlation to gold standard FISH analysis. On this basis, this array 
was suggested for use in clinical routine. Furthermore, this array enabled detection of 
the same prognostically relevant lesions as higher resolution arrays such as the 
Affymetrix 6.0 at lower cost.254 
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1.7: DNA methylation 
1.7 i: Establishment and maintenance of DNA methylation 
DNA methylation is a heritable epigenetic mark that involves the non-random 
addition of a methyl group to the fifth position of a cytosine ring within CpG 
dinucleotides (Figure 1G).  
 
 
Figure 1G. DNA Methylation. Represetation of the addition of a methyl group to the fifth 
position of the cytosine pyrimidine ring. 
 
DNA methylation is accompanied by concomitant histone modifications that play key 
roles in the control of gene activity and nuclear structure.255 For instance, DNA 
methylation and repressive histone marks create a condensed genomic structure that 
impedes the access or inhibits the binding of the transcription machinery resulting in 
gene inactivation. Conversely, the presence of activating histone marks and the lack 
of DNA methylation promotes an open chromatin structure supporting transcrition 
and gene activation (Figure 1H). Together, these actions function to regulate normal 
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cell differentiation, germline/tissue specific gene expression, genomic imprinting, 
embryogenesis and transposon gene silencing.256-260 
 
 
Figure 1H.  Diagram representing the interplay of histone modifications and DNA 
methylation in the control of gene activity and nuclear structure. TFs: transcription factors. 
 
During early mammalian development, a global de-methylation event occurs during 
pre-implantation. Once implanted, the embryo undergoes a wave of de novo 
methylation.261-263 De novo methylation patterns are established through the actions 
of DNA methyl transferases DNMT3A and B.264 The above actions lead to wide 
spread global DNA methylation with the exception of CpG islands. Once established, 
this global bimodal methylation pattern is faithfully maintained through the actions of 
the ‘maintenance’ DNA methyltransferase DNMT1 enzyme. This enzyme is recruited 
by the replication machinery to hemi-methylated DNA where it catalyses the transfer 
of methyl groups to newly synthesized DNA strands after DNA replication.256,265 
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During mammalian development, the bimodal DNA methylation pattern encounters 
further de novo DNA methylating and de-methylating events in order to bring about 
cell differentiation patterns. Unlike DNA methylation, mechanisms of DNA de-
methylation in mammals remain largely unexplored. That said, observations of global 
de-methylation during embryogenesis have pointed to both passive and active modes 
of action. Passive demethylation is said to occur when DNA methylation pathways 
are inactivated and DNA methylation is diluted after subsequent replication cycles.261 
Active DNA demethylation in mammals is thought to involve AID induced 
deamination of methyl cytosine to thymine.266 This is followed by a base excision 
repair by DNA glycosylase enzymes of the T/G mismatch.267,268 Alternatively, in 
vitro studies have shown that DNMTs 3a and 3B can also deaminate 5-methly 
cytosine.269 Imprinted regions are sheltered from active global demethylation as DNA 
methylation maintenance proteins such as PGC7 and DNMT1 protect them.258,270,271 
Moreover, it is also hypothesized that de-methylation may occur in somatic cells at 
sequence specific sites.261,269 
1.7 ii: DNA methylation regulation 
The success of epigenetic marks governing gene activity and nuclear structure 
depends on the strict regulation of the epigenetic machinery. DNMT enzymes, 
histone modification enzymes, DNA-methyl-binding proteins, non-coding RNAs, 
polycomb complexes amongst others work together to target specific genes for 
activation or repression. To date, the order and sequence in which these regulators 
crosstalk to co-ordinate epigenetic marks at specific targets is not fully elucidated. 
Nevertheless, clues from normal cell development and differentiation provide some 
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indication as to how DNA methylation may be regulated. In development, histone 
marks are thought to play a role in establishing DNA methylation. Here, they act as 
platforms permitting the recruitment, or inhibition of, the DNA methylation 
machinery.255,272 In contrast, DNA methylation is considered to play a role in 
maintaining histone modifications. Methylated DNA bound by methyl binding 
proteins (MECP2 and MBD2) is said to act as a platform guiding the reassembly of 
disrupted histone modifications post cell replication.255,273 
 
Protection of CpG islands during development 
Bimodal DNA methylation patterns set up during development are thought to be 
directed through specific histone modifications. For instance, unmethylated H3K4 
histones are associated with DNA methylation in many cell types.274,275 At 
unmethylated H3K4 histones, it is proposed that DNA methylation is permitted 
through DNMT3L which acts as a bridge to summon active DNMT3A and 3B 
enzymes to H3.272,276 H3K4 methylation is said to be regulated by components of the 
transcription machinery such as RNA polymerase II. Localized mainly at CpG 
islands, RNA polymerase II works to recruit histone methyltransferases to H3K4.276 
It is thought that repressive methylation marks at H3K4 inhibit the recruitment of de 
novo DNA methylating enzymes, keeping CpG islands free of DNA methylation 
repression. Alternatively, mouse studies indicate that CpG islands may escape de 
novo methylation through the action of cis acting sequences such as Sp1 sites that 
bind the Sp1 transcription factors and through unknown mechanisms hinder DNA 
methylation at these sites.277 
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Epigenetic regulation of cell differentiation. 
In embryonic stem cells, differentiation requires pluripotency genes to be silenced. In 
their active pluripotent state, these genes are found within an open chromatin 
structure bound by acetylated H3 and H4, methylated H3K4 and unmethylated DNA 
marks. Upon cell differentiation, gene silencing is thought to involve prompt 
repression by protein repressor molecules.255,278 This action is said to signal the 
recruitment of a histone methyltransferase G9 protein and histone deacetylase 
enzymes, promoting the formation of a more compact chromatin.279,280 The actions of 
G9 results in the methylation of H3K9, however at the same time by unknown means, 
H3K4 is demethylated. H3K9 methylation acts as a platform allowing the binding of 
heterochromatin proteins such as HP1. Additionally, G9 summons de novo DNA 
methyltransferases DNMT3A and 3B to promote DNA methylation resulting in the 
subsequent formation of condensed chromatin at these pluripotency genes.272,279,280 
Polycomb target genes in cell type specific DNA methylation 
Polycomb-multi-protein repressive complexes silence polycomb target genes vital for 
mammalian development.281 More specifically, polycomb target genes encode 
transcription factors important for embryogenesis, cell lineage specification, growth 
and proliferation.282 It is thought that polycomb silencing of these developmental 
genes may be overcome during germline differentiation. In embryonic stem cells 
(ESCs), it is proposed that histones carrying easily reversible, bivalent repressive 
(H3K27me3) and activating (H3K4me3) marks sit at these polycomb target genes, 
allowing them to actively switch between active and repressive states depending on 
the demands of the differentiating cell.283 
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Interestingly, at the DNA level, the majority of these target genes stay unmethylated 
during development.275 This is thought to be partially attributed to the fact that these 
genes are mainly affiliated to CpG island promoters that are largely safeguarded from 
DNA methylation during development. In certain instances, such as the 
differentiation of ESCs to neural precursors, DNA methylation of polycomb target 
genes has been described.275 DNA methylation of these genes is thought to be 
mediated by polycomb complexes. Polycomb response elements (PREs), regulatory 
sequence specific elements, are proposed to enable the binding of polycomb (PRCs) 
subunits, marking the gene for repression.284 Binding of EZH2, the histone 
methyltransferase subunit of the PRC2 complex, is known to catalyse the methylation 
of H3K27. In vitro studies indicate EZH2 to interact with the DNMTs to mediate 
DNA methylation of polycomb target genes.285 
1.7 iii: DNA methylation in tumorigenesis 
Today, it is widely accepted that alterations to the DNA methylome and changes to 
histone modification patterns contribute to cancer pathogenesis. In particular, DNA 
methylation of vital genes involved in key cellular pathways is now recognized as one 
of the hallmark mechanisms of aberrant gene silencing (Figure 1I).286 Moreover, 
hypomethylation of instable repetitive genomic regions is further thought to 
contribute to cancer (Figure 1I). Unlike genetic lesions, such as mutations and 
deletions, DNA methylation provokes gene silencing without changes to the DNA 
sequence.287 In some instances, aberrant DNA methylation is suggested as an early 
event in cancer occurring at the stem cell stage. However, other arguments support 
aberrant DNA methylation as a late event, in tumorigenesis. Many of the DNA 
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methylation changes found in cancer are said to merely reflect the patho-biology of 
long lived progressive tumour cells and that these changes are mostly indicative of 
passenger rather than driver epigenetic events.288 Overall, altered DNA methylation is 
one component in a very complex epigenetic network that co-operates with intrinsic 
cellular defects and tumour promoting extrinsic factors to aid carcinogenesis. 
Exon 1 Exon n
Exon 1 Exon n
Repeat region
Repeat region
Promoter
Promoter
Normal Cell
Cancer Cell
Transcription
No Transcription
unmethylated CpG
methylated CpG
Figure 1I. Illustration of DNA methylation in normal and cancer cells. (Adapted from Baylin 
2005)289 
 
1.7 iv: Hypermethylation 
As previously described, globally, DNA is largely methylated with targeted regional 
hypomethylation of most CpG islands in normal cells (Figure 1I). Vast DNA 
methylation covering repetitive genomic regions and transposable elements ensures 
the maintenance of genomic stability.260 On the other hand, hypomethylation of CpG 
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islands allows the transcription of vital genes governing normal cell growth, 
proliferation, differentiation and tissue specific gene expression.257,290 In cancer, the 
opposite DNA methylation pattern ensues where targeted promoter hypermethylation 
and global hypomethylation work in synergy with anomalous histone modifications 
and interaction proteins to disrupt gene regulation.256,287,291-293 Pivotal to 
carcinogenesis is the role of promoter DNA methylation and transcriptional silencing 
of vital tumour suppressor genes.92,287,292 This largely involves methylation of 
cytosines within densely populated CpG regions known as CpG islands spanning the 
5’ end of many genes within their promoters. Nevertheless, new evidence suggests 
that methylation of CpG island shores and shelf regions of low CpG density located 
outside the vicinity of traditional CpG islands are fundamental to gene silencing.294,295 
For instance, Doi et al have demonstrated a number of overlapping differentially 
methylated loci involved in normal tissue programming, epigenetic reprogramming to 
pluripotency and aberrant programming of cancer cells.294 Interestingly, these loci 
were shown to be predominantly contained within CpG island shores. These findings 
suggest that epigenetic changes encountered in cancer are likely due to the 
reprogramming of the normal pattern of tissue specific differentiation and highlight 
the importance of CpG island shores in regulating transcription of specific loci.294,295 
1.7 v: Hypomethylation 
In cancer, aberrant global hypomethylation has been proposed to inappropriately 
active possible oncogenic genes,260 little evidence of this has been documented. More 
importantly, hypomethylation of gene poor repetitive DNA sequences that account 
for up to 30% of the genome are suspected to contribute to genome instability.296-298 
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Furthermore, it has recently been described in mature B cell lymphomas that unlike 
global hypo-methylation previously implicated in cancer, gene specific hypo-
methylation can fraternize with local DNA hypermethylation during tumorigensis.299 
 
1.7 vi: DNA methylation and mutagenesis 
DNA methylation can further influence genome stability through the introduction of 
mutations at CpG sites. Methylated cytosines are subjected to a higher rate of 
mutagenesis relative to unmethylated cytosines.300 This is thought to occur due to an 
increased propensity of spontaneous deamination at methylated cytosines. These 
mutations account for a large number of known point mutations contributing to 
genetic disease and are said to account for up to 30% of all germline point 
mutations.301,302 Moreover CpG sites in the coding regions of TP53 are methylated in 
all human tissues.303 Approximately 25% of all inactivating mutations in cancer in 
general can be attributed to transitions at CpG dinucleotides.302 
1.7 vii: Role of DNA methylation in CLL 
Like other cancers, the genome of CLL patients is hypomethylated compared to PB 
mononuclear cells from healthy normal controls.304-306 Until recent times, epigenetics 
was explored solely on a gene to gene basis. Nevertheless, this candidate gene 
approach identified a number of DNA methylated promoters contributing to CLL 
pathogenesis. For instance, TWIST-2, a transcription factor and well known silencer 
of p53 function in other malignancies, was shown to be methylated predominantly in 
IGHV mutated patients.307 Similarly, silencing of ZAP70 through methylation has 
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been strongly correlated to IGHV mutational status.308 Additionally, loss or reduced 
expression of DAPK1 through promoter methylation has been shown in a large 
proportion of CLL.309 In mutated CLL, DNA methylation of CD38 and BTG4 has 
been correlated to a favourable outcome, whereas DNA methylation of HOXA4 has 
been affiliated to poor outcome.310 
More recently, a study by Rush et al has demonstrated the genome-wide methylation 
profiles of ten CLL patients.311 Using restriction landmark genome scanning (RLGS), 
a restriction enzyme, 2D gel electrophoresis method, only a limited number of CpG 
sites (~3,000) were analysed across the whole genome. Interestingly, between 2.5–
8.1% of the CpG islands were shown to be aberrantly methylated in CLL samples 
compared with normal controls. Moreover, 193 aberrantly methylated sequences were 
identified, of which 93% had CpG island characteristics and 90% showed homology 
to genes or expressed sequences. Many of the genes identified were transcription 
factors such as DERMO1, FOXE1, TBX3, and IPF1. Other loci known to play roles in 
the nervous system such as TBR1, GLRB, and PAK5 were also identified, however 
their role in CLL if any is still unknown. Finally, the GRM7 gene, a gene functioning 
in the possible inhibition of cyclic AMP signaling in the induction of apoptosis was 
identified as methylated in CLL patients.311 
With the advent of higher resolution microarray and sequencing technologies, overall 
DNA methylation scores have been indicated as strong independent predictors in 
CLL progression.312 Patients with a higher genome- wide DNA methylation index 
relative to their age expected index have been associated with an earlier indication for 
therapy and Rai stage IV disease.312 On the other hand, patients displaying a lower 
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index with respect to age have clinically stable, Rai stage 0-1 disease.312 Additionally 
these new technologies have allowed the interrogation of repetitive sequences in CLL 
patients. Here, aberrant hypomethylation at repeat sequences including ALU, LINES 
and SATα, is shown to be more marked in 17p deleted cases. In addition, a lower 
SATα methylation level has been shown to act as an independent marker predicting a 
shorter time to first treatment in CLL.313 Furthermore, the methylation profiles of 
CLL patients are shown to segregate according to CD38 expression.310 
1.7 viii: Disruption of DNA methylation regulatory mechanisms in 
tumourigenesis 
In cancer, the epigenetic machinery fall victim to destruction and disorganisation. The 
exact mechanisms involved in epigenetic deregulation are largely unknown. Genomic 
loss or mutation to the DNA methyltransferases and other regulatory molecules are 
suspected to contribute to epigenomic disarray. For instance, somatic mutations 
decreasing de novo DNMT3A activity has been found in up to 20% of acute myeloid 
leukaemia (AML) patients.314,315 Moreover, mutations in polycomb repressive 
complex components have also been described. For example, mutations at tyrosine 
641 in the SET methyltransferase domain of EZH2, are shown to change the substrate 
specificity of EZH2 for various methylation states at H3K27 in non-Hodgkin 
lymphoma (NHL).316 For instance, the Y641C mutation abrogates the enzymatic 
activity of EZH2 against unmethylated and mono methylated H3K27. Remarkably, 
this mutation allows this enzyme to carry out better catalysation and formation of 
trimethylated H3K27 compared to the wild type enzyme.316 Additionally, in myeloid 
disorders, inactivating mutations of EZH2 have also been reported.317 
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Altered expression levels and improper activation of the epigenetic machinery are 
also considered to be attributed to epigenetic disorder. For instance high expression 
of DNA methyltransferases are thought to be involved in the pathogenesis of some 
cancer cell types. Other studies have noted the over-expression of EZH2 to be 
associated with cancer progression. One study by Chen et al suggests the over 
expression of cyclin dependent kinases (CDKs) in cancer to aberrantly phosphorylate 
and activate EZH2.318 Other in vitro prostate cell line studies suggest that increases in 
EZH2 expression are due to genomic loss of miRNA 101.319 Interestingly, in MYC 
induced lymphoma, MYC has been implicated to stimulate EZH2 expression by 
repression of its negative regulator miR-26a, thus contributing to lymphomagenesis, 
therefore a regulatory role for miRNAs in the epigenetic control of gene regulation 
has been proposed.320 
1.7 ix: Use of DNA methylation markers in clinical routine 
In recent years, the plethora of genome wide DNA methylation studies have noted 
differentially methylated gene patterns in different cancers.299,321-323 In some 
instances, these methylation changes constitute tumour and tissue-specific changes 
that contribute to tumorigenesis,294,295 thus marking these genes as possible candidate 
prognostic markers and therapeutic targets in cancer. Despite the volume of these 
differentially methylated candidates, very few have graduated to be true bona fide 
prognosticators or therapeutic targets. One reason for this is the inability to decipher 
true tumour specific differentially methylated genes from normal tissue and patient 
specific changes.324 For instance, changes attributed to such factors as age, sex,325 
hormones (androgens)326 and diet complicate matters since increasing age and poor 
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folate diets leading to insufficient in vivo methyl stores can aid hypomethylation 
events.327 Furthermore, changes attributed to patient treatment regimes and disease 
progression may mask true tumour specific changes. 
Another barrier preventing the possible use of such candidate markers in clinical 
routine is the question of methylation stability over time. To date, little evidence 
exists on this issue, since many studies are based on snap shot analysis of different 
individuals and diseases.328 One study investigating bladder cancer metachronous 
tumours from two individuals, has shown DNA methylation to be relatively stable 
over time both within the individual and between patients.329 In contrast, a study by 
Bjornsson et al328 focusing on absolute inter- and intra-individual DNA methylation 
changes have identified substantial inter-individual age variation and considerable 
differences occurring over time within individuals that would otherwise be missed by 
group averaging. Interestingly, these changes were shown to be clustered within 
family members. Hence, these findings support the age related loss of normal 
methylation patterns as a mechanism for the late onset of disease and further highlight 
the possible influence of genetic background on DNA methylation changes.324,328 
That said, a study of DNA methylation in 40 monozygotic twins found 14 to have a 
disconcordant degree of total DNA methylation, particularly those over 28 years of 
age.330 Thus, the latter finding is indicative of environmental factors that are already 
known to alter DNA methylation. While issues of stability and specificity prevail and 
since the clinically relevant level of DNA methylation conducive to target gene 
inactivation is unknown, use of differential DNA methylation changes as candidate 
prognostic markers or treatment targets remain to be seen. 
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1.8. DNA methylation technologies 
DNA methylation quantification methods have evolved rapidly over the past two 
decades. Initially, global DNA methylation levels were estimated using high 
performance liquid chromatography (HPLC).331,332 This method, although highly 
quantitative, failed to give information on the exact sequences afflicted with aberrant 
DNA methylation. The need for region specific analysis, provoked the development 
of cytosine methylation enrichment techniques employing methylation sensitive 
restriction enzyme (MRE) digestion,333 McrBC methylation dependent enzyme 
fractionation,334 5’-methylcytosine antibody immuno-precipitation,298 methyl-binding 
protein capture methods335 and chemical bisulfite treatment approaches.336 Applying 
enriched methylated DNA to various microarray and sequencing technologies has 
allowed the interrogation of DNA methylation at individual regions, particularly 
within CpG islands and gene promoters. More recently, advancing technologies have 
enabled a more global view, uncovering the DNA methylation status of non CpG 
island sites and repetitive sequences throughout the genome.337 
 
Early sequence specific genome wide DNA methylation investigations utilised the 
(RLGS) platform, an MRE based 2D gel method.338,339 This technology explored the 
whole genome on a limited scale, deciphering methylation events contained only 
within MRE recognition sites within a limited number of genes as reviewed in Fouse 
et al.337 Plagued by false positive and negative results originating from incomplete 
digestion the true reflection of DNA methylation at these sites is often hampered, as 
reviewed in Esteller et al.297 Considering the disadvantages of RLGS and the fact that 
it only assess ~3,000 CpG sites,311,338 the need for more reliable, higher resolution 
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analysis paved the way for the use of high fidelity bisulfite treatment in combination 
with microarray technology. 
The onset of bisulfite conversion revolutionised DNA methylation analysis. This 
allowed the reproducible change of unmethylated cytosines to be deaminated to 
uracil, leaving methylated cytosines unchanged as they are refractory to treatment.336 
However, bisulfite treatment reduces the sequence complexity of the genome 
complicating its application to oligonucleotide arrays. Nevertheless, today bisulfite 
treatment is considered the gold standard method of cytosine DNA methylation 
enrichment336 for many high throughput DNA methylation sequencing platforms such 
as shotgun bisulfite sequencing340 and DNA methylation microarray Illumina 
human27 and human450 technologies. The 27K array allows the investigation of 
~28,000 CpG sites covering ~14,000 genes, whereas the 450K array covers ~ 485,000 
sites across the whole genome. These arrays, particularly the latter permit, the 
interrogation of CpG sites both within gene promoters and outside of their coding 
regions.341 
In brief, microarray platforms interrogating DNA methylation at pre-determined CpG 
sites342-344 generally offer less coverage (103-106) of the DNA methylome relative to 
DNA methylation sequencing methods and next generation technologies (106-
107).337,345,346 Nevertheless, the microarray comprehensive high throughput arrays for 
relative methylation (CHARM) tiling array provides a high CpG coverage similar to 
that of some sequencing technologies ~106.334 In general, microarray platforms based 
on the hybridization of bisulfite treated and MRE prepared DNA can provide single 
CpG site resolution. In contrast, microarray platforms utilising immunoprecipitated or 
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methyl binding protein enrichment, quantify DNA methylation across a region of 
~1000 base pairs. Hence, the latter provide higher coverage of the genome yet at a 
poorer resolution (as reviewed in Fouse et al).337 Such techniques as MeDIP and 
MIRA-Chip rely on the faithful precipitation of DNA methylated sites using specific 
antibodies against 5’methylcytosine or methyl CpG binding proteins which bind 
methylated cytosines. Enriched DNA is then hybridized to a genomic 
microarray.298,335 A summary of the advantages, disadvantages and characteristics of 
some of the available DNA methylation platforms is described below in Table 1B and 
1C. 
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Table 1B: Summary of DNA methylation microarray platforms. 
Microarray  
Technology 
 
Pre-
Processing 
CpG site  
Coverage/  
Resolution  
Advantages Disadvantages 
Illumina  
Human27 
Bisulfite 
conversion 
~27,000/ 
~1 bp 
Cheap 
Reliable 
Single bp  
resolution 
Low coverage 
Promoter biased  
No assessment of 
repeat regions 
Illumina  
Human450 
Bisulfite 
conversion 
~450,000/ 
~1 bp 
Reliable 
Single bp  
resolution 
Low coverage 
Inability to assess 
repeat regions 
HELP-Chip 
Promoter array 
MRE 
digestion 
105/~1000 bp High genome  
coverage 
 
Low resolution 
Limited to MRE sites 
MIRA-Chip 
(CGI array) 
(Global  
tiling array) 
Sonication  
or  
MRE/MB 
column 
105/~1000bp 
 
106/~1000 bp 
High genome 
coverage 
No need for 
ssDNA 
Low resolution 
Limited to MRE sites 
MeDIP-Chip 
Promoter array 
Global tiling 
array 
 
Sonication/ 
IP 
 
105/~1000 bp 
106/~1000 bp 
High coverage 
Not limited by  
restriction sites 
Low resolution 
Enrichment bias 
towards high density 
CpG sites 
Needs ssDNA 
CHARM 
tiling array 
McrBC  
digestion 
106/~1000 bp High coverage 
Less biased 
towards high 
density CpG 
sites compared to 
MeDIP 
No single site  
resolution 
Limited to McrBC 
sites 
Can not interrogate 
low density CpG 
sites 
IP: immunoprecipitation, MRE: methylation sensitive restriction enzyme, CGI: CpG island, MB 
column: methyl binding protein column, CHARM comprehensive high throughput arrays for relative 
methylation. HELP- HpaII tiny fragment enrichment by ligation mediated PCR. MeDIP- methylated 
DNA immunoprecipitation, MIRA: methylated CpG island recovery assay, ssDNA: single stranded 
DNA. Adapted from Fouse et al 2010.337 
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Table 1C: Summary of DNA methylation sequencing platforms 
 
IP: immunoprecipitation, MRE: methylation sensitive restriction enzyme, HELP- HpaII tiny 
fragment enrichment by ligation mediated PCR. MeDIP- methylated DNA 
immunoprecipitation, MIRA Adapted from Fouse et al 2010.337 
 
 
Although all the aforementioned technologies offer useful information, interpretation 
of observations from these methods often need to be independently reconfirmed with 
alternative methods. Semi-quantitative methods such as methylation specific PCR 
(MSP)347 and bisulfite sequencing are often employed.348 MSP, although easy to 
implement, is restricted in that it solely interrogates the CpG sites covered by the 
primer. Unlike MSP, bisulfite sequencing is a labour intensive technique. That said, 
bisulfite sequencing is much more advantageous than MSP since it readily 
interrogates CpG sites contained within the amplified region determined by the 
primers. Fully quantitative techniques such as pyrosequencing, can overcome some of 
the disadvantages of the former methods. Specifically, pyrosequencing easily allows 
the quantification of DNA methylation across a chosen site, often containing a 
number of CpG sites with minimal DNA input.349,350 
Sequencing 
Platforms 
Pre-
processing 
CpG site  
Coverage / 
Resolution 
Advantages Disadvantages 
Methyl-seq 
/Help-seq  
MRE 
digest 
105-106/~1 bp High coverage 
Interrogates  repeat 
sequences 
Single bp resolution 
Limited to MRE 
sites 
Shotgun  
Bisulfite  
sequencing 
Bisulfite 
/sonication 
107/~1 bp High coverage 
Interrogates  repeat 
sequences 
Single bp resolution 
Difficulties in 
assembling  
bisulfite converted 
sequences  
MeDIP-seq Sonication/ 
IP 
107/ 
200-300 bp 
High coverage 
Interrogates  repeat 
sequences 
No single site 
resolution 
Complicated to 
analyse 
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1.9: Epigenetic based treatment 
Epigenetic defects are heritable changes that do not affect DNA sequences; hence 
their effects are potentially reversible through the use of methyl inhibitors and histone 
deacetylation drugs. Today, the use of hypo-methylating drugs 5-azacytidine (5’aza) 
and its more potent counterpart 5-aza-2’-deoxycytidine (DAC) has been approved for 
the treatment of myelodysplastic syndrome patients. The use of histone deacetylase 
inhibitors also represents another group of potential drugs that can be used in 
epigenetic cancer therapy. Recently the first one of its type, suberoylanilide 
hydroxamic acid (SAHA), has been approved for the treatment of cutaneous T cell 
lymphoma.351 
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2) THESIS AIMS 
The overall aim of this thesis was to screen for genetic and DNA-methylation events 
in divergent CLL prognostic subgroups and investigate DNA methylation over time 
and within different CLL compartments. The specific aims were as follows: 
 
- To determine the frequency of IGHV3-21 gene usage among a Swedish population-
based cohort using Sanger sequencing and assess the impact of IGV3-21 stereotypy 
status on clinical outcome. (Paper I) 
 
-  To investigate genomic alterations in CLL patients expressing stereotyped and non-
stereotyped IGHV3-21 and IGHV4-34 BCRs using 250K SNP arrays. (Paper II) 
 
- To study DNA methylation profiling in prognostically diverse CLL subsets using 
27K DNA methylation arrays. (Paper III) 
 
- To evaluate the contribution of time and microenvironment on the global DNA 
methylation profiles of CLL patients, by assaying patient-matched diagnostic and 
follow-up samples and patient-matched LN and PB samples on 450K DNA 
methylation arrays. (Paper IV) 
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3: MATERIALS & METHODS 
3.1: Patient samples and patient characteristics 
In Paper I, peripheral blood (PB) was obtained form 337 patients at diagnosis 
including, 325 CLL and 12 CLL/small lymphocytic leukaemia (SLL) cases from the 
Swedish cohort of a Scandinavian population-based case-control study called SCALE 
(Scandinavian Lymphoma Etiology).352 
In Paper II, tumour material from 101 CLL patients was obtained from four 
cooperating institutes in France (n=15), Greece (n=25), Denmark (n=4) and Sweden 
(n=57). Samples mainly originated from peripheral blood (n=88), although samples 
from spleen (n=5) and bone marrow (n=8) were also included. In total, 42 IGHV3-21 
samples, encompassing 29 subset #2 and 13 non-subset #2 cases, and 59 IGHV4-34 
samples, comprising of 17 subset #4, 8 subset #16 and 34 non-subset #4/16 cases 
were analysed. Subsets were defined according to Stamatopoulos et al and Murray et 
al.5,6 A CLL sample set (n=203) from a recent array study was used for comparison 
purposes.183 
In Paper III, 23 CLL samples (6 IGHV mutated, 7 IGHV unmutated and 10 IGHV3-
21) were obtained from the Biobank at the Department of Pathology, Uppsala 
University Hospital, Sweden. All samples were derived from peripheral blood. For 
validation experiments, an independent set of 10 and 50 CLL samples were analysed 
by MSP-PCR and RQ-PCR respectively. For control purposes, one peripheral blood 
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mononuclear cell (PBMC) sample, one CD19 sorted B-cell sample and one negative 
whole-genome amplified DNA control were additionally analysed. For comparison 
purposes, 2 CLL EBV transformed cell lines (I83 derived from a mutated CLL 
patient and HG3 derived from an unmutated CLL patient) were included for analysis. 
In Paper IV, a total of 36 PB CLL samples obtained from the Swedish cohort of the 
SCALE study352 were chosen for analysis. To study the DNA methylation profiles of 
IGHV mutated and unmutated subgroups, sorted PB samples derived form 9 IGHV 
mutated and 9 unmutated patients at diagnosis were analysed. Sorted PB samples 
derived from these same patients were taken at follow-up to investigate DNA 
methylation over time. (Patient-paired samples: IGHV mutated cases n=9 cases at 
diagnosis and n=9 cases at follow-up and IGHV unmutated cases n=9 cases at 
diagnosis and n= 9 cases at follow-up) In addition, a separate set of 10 patient-
matched PB and LN samples collected from biobanks at Uppsala University and 
Linköping University hospitals were analysed. PB from three age-matched normal 
individuals and one whole-genome amplified DNA derived from PB were included as 
controls. 
All samples were diagnosed according to the WHO classification and the 
International Workshop on Chronic Lymphocytic Leukaemia criteria (IWCLL).28 In 
Paper I, samples with highly variable tumour load were included for analysis. In 
Papers II and III, only samples with ≥70% tumour cell content were included for 
analyses. In Paper IV, all samples were CD5+/CD19+ sorted. Clinical and molecular 
data characterising Binet stage, IGHV mutational status, treatment and survival 
status, and chromosomal alterations are detailed in Papers I-IV.  
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3.2: Ethical Approval 
All samples and clinical data included in the research described herein were collected 
following strict ethical guidelines. Written informed consent was obtained according 
to the Declaration of Helsinki. All personal data was de-personalised prior to analysis 
and publication to maintain the privacy of the participant. Traceability procedures 
were put in place allowing full traceability of patient samples and clinical data should 
the participant wish to withdraw from such studies at any point. Each study was 
approved by the local Ethics Review Committee from all collaborating institutions 
mentioned in the relevant studies. Registration numbers of the ethical review board 
decision from Uppsala University and the Karolinska Institute Sweden are as follows 
Ups:01-082 and 2006/964-31/2. 
3.3: IG gene sequencing 
In all Papers, CLL patients were characterized according to IG gene usage, 
mutational status and the presence of stereotyped and non-stereotyped receptor 
sequences.5,6 These characteristics were detected through PCR amplification of 
gDNA or cDNA using IGHV gene family specific framework 1 or leader primers.353 
Consensus primers for the kappa/lambda FR1 and IGKJ/IGLJ genes6,147,149 were used 
to amplify light chain IG rearrangements. Following amplification, most clonal 
products were sequenced using the Big Dye terminator cycle sequencing reaction kit 
(Applied Biosystems, Foster City, CA). Where direct sequencing was unsuccessful, 
gel purification (Qiagen, Venlo, Netherlands) and/or cloning prior to sequencing was 
performed. Sequences were then aligned in the IMGT database using the IMGT/V-
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QUEST online tool (http://www.imgt.org).354 IGHV genes were denoted unmutated 
where a ≥98% identity to the corresponding germline gene was determined. 
Sequences with <98% identity were considered mutated. In Paper I, IGHV unmutated 
cases were further classified into truly unmutated (100% identity to germline), 
minimally (99-99.9% identity) and borderline mutated (98-98.9% identity). 
Stereotypy status was determined based on established molecular IG sequence 
criteria.5,6 
3.4: 250K Affymetrix SNP array 
In Paper II, 250K NspI SNP-arrays were applied to study CNAs and CNN-LOH 
events in IGHV3-21 and IGHV4-34 stereotyped and non-stereotyped samples. Array 
experiments were performed according to the standard protocols for Affymetrix 
GeneChip® Mapping NspI-250K arrays (Figure 3A) (Gene Chip Mapping 500K 
Assay Manual (P/N 701930 Rev2), Affymetrix Inc, Santa Clara, CA, USA). 
Subsequent to array scanning using the GeneChip® Scanner 3000 7G, probe level 
normalisation and SNP calling were accomplished using Affymetrix GeneChip® 
Genotyping Analysis Software (GTYPE) 4.1. 
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Figure 3A The 250K Affymetrix SNP array contains 262,000 SNP probes covering the 
whole genome. In short, the tumor DNA is enzymatically fragmented using the NspI 
restriction enzyme and adapters are added allowing PCR amplification of the fragments. 
After amplification the fragments are further fragmented and end labeled. Following 
hybridization of these labeled fragments to the array, copy number is estimated based on the 
ratio of fluorescence signals detecting gains and losses. (Adapted from affymetrix.com)355 
 
Single sample QC was performed using the Dynamic model algorithm and genotype 
calls were made using the BRLMM algorithm.356 Quality control measures were 
given as a neighbor score. This score was calculated by averaging the euclidean 
distances between the log2 ratios of 5 consecutive SNPs. A neighbor score of ≤0.4 
was applied as cut-off for sample inclusion. Log transformation of the data producing 
log2-ratios allowed for a more symmetrical data distribution. Subsequently, copy-
number normalization was performed using the Copy Number Analysis Tool (CNAT) 
4.0.1 and normal samples (n=82) previously run at the Uppsala Array Platform were 
used as a reference set for comparison. 
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Copy-number analysis using the BioDiscovery Nexus Copy Number 3.0 software 
(BioDiscovery, El Segundo CA, USA) operating the Rank Segmentation algorithm 
was employed. CNAs were defined on significance thresholds (p-value) of 1x10-6 and 
a log2ratio cut-off at ±0.2 for regions sized 200-500 kbp and ±0.15 for regions >500 
kbp, respectively. These settings were defined through previously described real-time 
quantitative PCR (RQ-PCR) validation experiments.183 To exclude polymorphic 
regions, CNAs that overlapped with >50% of a known CNV region were not 
considered as true CNAs and excluded from analysis. CNN-LOH analysis was 
performed using SNP array-data, taking into account the fraction of normal cells 
indicated from the flow-cytometry data.357 CNN-LOH regions larger than 3 Mbp with 
less than 50% overlap to CNVs were acknowledged as legitimate CNN-LOH events. 
3.5: Illumina Infinium HumanMethylation27 and 
HumanMethylation450 BeadChip array 
In Paper III, the HumanMethylation27 array (Illumina, San Diego, USA) was applied 
to study the differences in methylation profiles between mutated, unmutated and 
IGHV3-21 CLL patients. In Paper IV, the HumanMethylation450 array was 
employed to study genome wide methylation differences between 1) IGHV mutated 
and unmutated subgroups, 2) paired diagnostic and follow-up CLL samples and 3) 
paired matched PB and LN CLL samples. All samples underwent bi-sulfite 
conversion of genomic DNA according to the standard EZ DNA Methylation Kit 
protocol. (Zymo Research, Orange, CA, USA). 
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Following conversion, the DNA was whole-genome amplified, enzymatically 
fragmented, precipitated, resuspended and hybridized over night to locus specific 
oligonucleotide primers. The 27K array based on the infinium I assay design employs 
locus specific oligonucleotide primers that are linked to individual bead types (Figure 
3B). Two bead types correspond to each CpG locus – one to the methylated cytosine 
(C) and the other to the unmethylated thymine (T) state. Following hybridization, 
single base primer extension allows the detection of C or T nucleotides through a 
fluorescent signal that is measured using the Illumina BeadStation GX scanner. The 
intensities of the unmethylated and methylated bead types are measured and a DNA 
methylation value, described as the Beta values or methylation index (MI), is 
recorded for each locus via BeadStudio software. Unlike the 27K array, the 450K 
array employs both infinium I and infinium II technologies (Figure 3B). The infinium 
II design utilizes a single bead type. In this case, the methylation status is calculated 
after hybridisation at the single base extension phase. The intensity of the fluorescent 
signal emitted from this extension is scanned and measured. Since the 450K array 
elicits the use of both infinium I and II assay designs, the array can increase genome 
wide coverage across CpG sites compared to the limited coverage of the 27K array. 
In both array types, the methylation status for each detected CpG can range between 0 
(completely unmethylated) to 1 (completely methylated). MI cut-offs of ≥0.7 and 
≤0.4 (average of all MI values in each group) were considered methylated and 
unmethylated, respectively. 
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Figure 3B. Diagram representing the principals of the HumanMethylation 27 and 450 
BeadChip arrays. The 27K array is based solely on the infinium I design employing two bead 
types per locus, one for the methylated (M) and one for the unmethylated (UM) state. The 
450K array is based on both Infinium I and II design. The Infinium II design uses only a 
single bead type (S). The methylated state is determined at base pair extension. (Adapted 
from Illumina.com)341 
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3.6: Bioinformatic analysis of the Illumina human27 and 450 
DNA methylation array data 
To systematically identify differentially DNA methylated genes in paper III, 
bioinformatic analysis of the methylation data was carried out using the statistical 
computing language R (http://www.r-project.org) software. Similarly for Paper IV, 
bioinformatic analysis of the methylation data was conducted using the R based 
illumina methylation analyzer (IMA) package. In both studies, raw data was quantile 
normalized, arcsin transformed and an empirical Bayes moderated t-test was then 
applied using the ‘limma’ package to identify differential methylation patterns 
between the various sample comparisons. The p-values were adjusted using the 
method of Benjamini and Hochberg, and a level of p<0.05 was used as a cutoff.358 In 
Paper III, to ensure only CpG sites with a large methylation differences were 
obtained, an average geometric difference in MI of 0.45 between the IGHV mutated 
and IGHV unmutated subgroups, 0.35 between the IGHV3-21 and IGHV mutated 
subgroups and 0.35 between IGHV3-21 and IGHV unmutated subgroups was 
applied. 
In Paper IV, an average difference in MI of ≥0.40 was applied to decipher recurrent 
differentially methylated sites between the IGHV mutated and IGHV unmutated 
patients at diagnosis. To identify recurrent methylation differences between paired 
diagnostic and follow-up samples, and patient matched samples from different 
anatomical compartments, a paired t-test was adopted. Again, P values were adjusted 
according to the Benjamini and Hochberg method and a P value of <0.05 was applied 
as a cut-off. To determine recurrent differentially methylated sites across the paired 
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over time and compartment samples, an average difference in MI of >0.20 was first 
applied. On recognising the low number of recurrent sites passing the >0.20 threshold 
an average difference ≤0.20 was employed. In order to assess the likelihood of small 
methylation differences representing technical variation, R2 values were calculated 
for diagnostic/follow-up pairs and patient matched compartment pairs and compared 
to the R2 value reported by Illumina for technical replicates assayed on the 450K array 
(R2>98). 
To assess non-recurrent intra-individual methylation differences between patient-
paired samples and patient-matched compartment cases that would otherwise be 
masked by averaging of the data, intra-individual analysis based on non transformed 
data of the paired samples was conducted. Specifically, the number of sites differing 
by ≥0.4 in beta value (MI) between the individual diagnostic and follow-up pairs was 
employed. Sites differeing by ≥0.4 in MI between the LN and PB patient-matched 
pairs was first applied to determine non recurrent differences across the 
compartments. Subsequently a filter of ≥0.3 in beta value was assessed. 
3.7: Methylation-specific PCR analysis  
In Paper III, methylation array results were verified using methylation specific 
(MSP)-PCR for 4 differentially methylated genes. Methylated specific primers were 
designed according to Li and Dahiya selection criteria using the Methprimer design 
software (Bisearch, San Francisco, USA).359 Standard PCR protocol was applied and 
bands were visualised on a 2% agarose gel. 
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3.8: Real-time quantitative PCR analysis  
In Paper III, to investigate the influence of methylation status on gene expression of 
specific genes, the expression of 4 differentially methylated genes were tested using 
RQ-PCR on 60 independent samples. Total RNA was extracted using the RNA 
extraction Kit (Qiagen, Venlo, Netherlands) and reverse transcription was performed 
using the MMLV-RT kit (Invitrogen, Carlsbad, CA) and random hexamers 
(Fermentas, Burlington, Canada) according to the manufacturer’s protocol. RQ-PCR 
primers were designed using the Primer3 software (Broad institute, Boston, USA) 
(www.wi.mit.edu/). RQ-PCR analysis was performed using 2X SYBR green master 
mix (Fermentas, Burlington, Canada) and expression was analyzed using the 
Stratagene Mx 3005p (Stratagene, La Jolla, CA, USA) detection system and Max Pro 
QPCR software (Stratagene). 
3.9: Bisulfite sequencing  
To confirm the methylation status of individual genes in Paper III, two genes 
underwent bi-sulfite sequencing. Bi-sulfite sequencing primers (BSP) were designed 
according to primer selection criteria as outlined by Li and Dahiya. 359 A touch down 
PCR was applied as described in Paper III. The PCR product was cloned using the 
Invitrogen TOPO TA cloning kit-2.1 TOPO vector (Invitrogen, Carlsbad, CA, USA), 
and 10-12 positive clones per sample were selected. The product was subsequently 
exonuclease/shrimp alkaline phosphatase (ExoI/SAP) purified and sequenced using 
the BigDye Terminator Cycle Sequencing Reaction Kit (Perkin-Elmer, Foster City, 
CA). Sequences were aligned and analyzed using the bisulfite sequencing web-based 
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tool BiQ Analyzer software (Max-Planck Institut für informatik, Saarbrucken, 
Germany). 
3.10: 5-aza-2’-deoxycytidine and Trichostatin A treatment 
To test for the re-expression of methylated genes after methyl inhibitor and/or histone 
deacetylase inhibitor treatment, primary CLL cell samples and CLL cell lines were 
cultured in supplemented RPMI-1640 media as outlined in Paper III. Confluent cells 
were subdivided and cultured over 3 days in supplemented RPMI media treated with 
one of the following treatments: 1) medium containing 5-aza-2’-deoxycytidine 
(DAC) (5µM/L, Sigma Aldrich, St. Louis, MO) for 72 hours (medium was changed 
every 24 hours), 2) medium containing Trichostatin A (TSA) (500nM/lit, Sigma 
Aldrich, St. Louis, MO) for the last 24 hours, and 3) medium containing DAC for 48 
hrs followed by addition of TSA for 24 hrs. Control cells were cultured in similar 
way with no drugs added. 
3.11 Pyrosequencing 
In Paper IV, pyrosequencing was chosen to validate the methylation status of selected 
differentially methylated genes seen on the Illumina 450K methylation array. 
Pyrosequencing, a sequencing by synthesis method, gauges the primer directed and 
polymerase extended incorporation of specific nucleotides to a bisulfite converted 
DNA template. Pyrosequencing quantitatively measures the incorporation of 
nucleotides since the amount of pyrophosphate emitted is ultimately converted to a 
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proportional light signal. The degree of methylation is determined at each CpG 
position in the analysed sequence through the ratio of T and C.350 
First, bisulfite converted DNA was PCR amplified using a forward and 5’ biotin 
labeled reverse primer pair designed using the PyroMarkTM software (Qiagen, Venlo, 
Netherlands). Primers were designed to cover the exact CpG sites identified on the 
450k methylation array. Once amplified, PCR products were immobilized on 
strepavidin sepharose beads, denatured to form single strands and annealed to the 
sequencing primer (designed by PyroMark TM software). Separation and annealing 
steps were enabled by the PyroMark Q24 prep vacuum workstation. Following 
annealing, CpG site methylation analysis was performed on the PyroMark Q24 
pyrosequencing instrument and interpreted on the PyroMark Q24 software (Qiagen, 
Venlo, Netherlands). 
3.12. Statistical analysis 
In Paper I, the statistical significance of IGHV3-21 gene frequency differences 
incurred across our study and others was determined by a chi-squared test. Overall 
survival was measured from the diagnosis date until the date of death or last known 
follow-up. Time to treatment was calculated from the diagnosis date to the date of 
first known treatment. Kaplan-Meier analysis visualized OS and TTT within the 
different groups studied in the form of survival curves. A log rank test was employed 
to determine the statistical differences in OS and TTT between the studied groups. 
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In Paper II, statistical differences in the frequency and size of the alterations between 
the studied groups were calculated via the Chi-square test, one way ANOVA test and 
t-test where appropriate. In Paper III, statistical differences in expression as 
determined through RQ-PCR were calculated by a t-test and represented in box plot 
graphs. In Paper IV, statistical differences in the level of methylation determined by 
pyrosequencing were calculated using a t-test. All statistical analyses were performed 
using the Statistica 8.0 and 10.0 software (StatSoft, Tulsa, OK). 
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4: RESULTS & DISCUSSION 
4.1: Paper I: IGHV3-21 gene frequency in a Swedish 
population-based cohort 
A decade ago, the importance of IGHV3-21 gene usage as an independent prognostic 
marker was discovered.135 In light of IGHV3-21 as a poor prognosticator irrespective 
of mutational status, a myriad of studies were then dedicated to investigate the 
prevalence and clinical outcome of this gene. Across European and North American 
CLL cohorts, CLL was established to display a biased IGHV gene repertoire with an 
over-representation of IGHV1-69, IGHV4-34, IGHV3-7, IGHV3-23 and IGHV3-21 
genes.3,134,135,149 Additionally, studies continually demonstrated both mutated and 
unmutated IGHV3-21 patients to experience a poor survival, similar to that of other 
unmutated CLL cases utilising alternative IGHV genes.137,150,152 However, on 
comparing the predominance of this poor prognostic IGHV3-21 gene across different 
geographical regions, large variances in IGHV3-21 gene frequency were continually 
noted. Remarkably, Scandinavia has been shown to present with a high IGHV3-21 
gene frequency (10-13%)4,135,137,150 compared to other regions namely the USA and 
Southern Europe (3-4%) (Table 4.1 A).5,151,152 
On recognising the geographical bias of IGHV3-21 and the particularly poor clinical 
outcome of these patients, attentions turned to the biological reasons behind such 
findings. Sequencing of IGHV3-21 gene rearrangements noted a large proportion of 
 81 
cases to carry stereotyped HCDR3 sequences. 5,135,137,147,149 Moreover these 
stereotyped cases were shown to frequently present with restricted IGLV3-21 gene 
usage.137,149,150 Stemming from the findings of IGHV3-21 over representation and 
IGHV3-21 BCR sequence restriction, the prospect  of a specific antigen contributing 
to IGHV3-21 leukemogenesis was suggested.25,144,148,360 Interestingly, some studies 
have reported stereotyped IGHV3-21 (subset #2) patients to have a shorter time to 
progression relative to their non sterotyped IGHV3-21 counterparts.149 That said, 
other studies have not found such a correlation, thus no consensus exists regarding 
the clinical impact of IGHV3-21 stereotypy in CLL. 
Since many of these above findings are based on hospital-based CLL cohorts and are 
subjected to large cohort selection bias, it was consequently of interest to determine 
the frequency of IGHV3-21 gene usage among a CLL Swedish population based 
cohort (n=337). Subsequently, we attempted to address the clinical impact of IGHV3-
21 stereotypy and mutational status on CLL patient survival and progression. 
This population-based study reports the Swedish IGHV3-21 frequency to be 6.5%. 
Although this frequency is lower compared to previous Scandinavian rates 
constructed from university hospital data (10-13%),4,135,137,150 the frequency still 
remains higher relative to other large studies form the USA152 and the Mediterranean 
(3-4%) (Table 4.1 A).5,151,152 In light of this finding, the differences in frequency 
encountered between small hospital-based cohorts demonstrating an over-
representation of IGHV3-21, such as Ireland (7.9%),361 Britain (9.6%),154 and the 
Ukraine (5.8%)153 must be interpreted with caution, since discrepancies can be 
introduced by such factors as sample size and cohort selection bias. That said, despite 
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the increased tendency to select for more aggressive CLL cases in hospital-based 
studies, such reports from the Mediterranean and USA still find IGHV3-21 frequency 
to remain rather low (3-4%).5,151,152 Despite the different nature of the CLL cohorts 
studied, in this population-based report versus our previous hospital–based study we 
reconfirmed that a true IGHV3-21 geographical bias exists in Sweden. 
 
Table 4.1 A Comparison of IGHV3-21 gene frequency in large CLL cohorts from 
Scandinavia, Mediterranean and USA  
IGHV3-21 
cohort  
 
Current 
Swedish 
population-
based study 
 
 
Hospital-based  
Scandinavian 
study4 
 
Multi-
centre 
Italian  
study151 
 
Multi- 
centre  
Mediterranean 
Study5 
 
 
USA 
Study  
152
 
IGHV3-21 6.5 %  10.1  % 4.1 % 3.5 %  2.6% 
 
Other explanations for disparity in global IGHV3-21 frequency may be explained by 
differences in genetic background, influencing the expansion of the IGHV3-21 
precursor CLL cells. Interestingly, Iranian CLL hospital based studies have shown no 
IGHV3-21 usage.362 Alternatively, it is plausible that the IGHV3-21 geographic bias 
may reflect differences in the patient environment and the type of antigen exposure 
encountered. Given that we find a similar proportion of stereotyped cases in this 
report (14/22, 63.6%) as in other western CLL cohorts from the Mediterranean area 
(16/32, 50%),5 Italy (32/58, 55.2%)151 and the US (25/63, 39.9%),152 the notion of a 
native antigen primarily encountered in Sweden impacting on IGHV3-21 gene 
frequency and leukemogenesis is less reasonable. On the other hand, non-stereotyped 
IGHV3-21 BCRs, given their heterogeneous molecular structure, may enable the 
binding of diverse antigens during leukemogenesis. 
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This study, like many previous, has established IGHV3-21 patients to experience a 
very poor overall survival (Figure 4.1 A).137,147,149-151 However, the clinical impact of 
IGHV3-21 stereotypy is less clear. Given the suggestion of specific antigen 
involvement in stereotyped IGHV3-21 CLL and since IGHV3-21 stereotypy has been 
affiliated to disease progression,5,149,151 it was of particular interest to determine its 
clinical impact on the disease. In a large collaborative European study incorporating 
90 IGHV3-21 cases collected mainly from Sweden and Germany, no differences in 
survival were encountered between stereotyped IGHV3-21 patients and their non-
stereotyped counterparts.150 In support of these findings, studies from the US and 
Italy encompassing 63 and 37 IGHV3-21 cases respectively corroborated the 
disassociation between survival and stereotypy. As mentioned, smaller studies from 
the Mediterranean (n=16 and n=32) have shown IGHV3-21 cases with stereotyped 
receptors to undergo a shorter time to progression relative to non-stereotyped 
cases.5,149 Perhaps these findings imply that the nature of the antigen may influence 
patient clinical behavior. That said, our study could not corroborate this finding, since 
no difference in time to treatment was seen between stereotyped and non-stereotyped 
IGHV3-21 patients (p=0.68) (Figure 4.1 A). 
Again, the possible reason for this disparity between our study and others is perhaps 
explained by differences in cohort type and size. Alternatively, biological reasons 
such as a higher expression of the negative prognosticator CD38 and the higher 
occurrence of del(11q) documented in stereotyped relative to non-stereotyped 
IGHV3-21 cases may partially explain the poor disease course seen in these earlier 
studies.147 Although this study showed a trend towards having a higher frequency of 
del(11q) in stereotyped IGHV3-21 patients, a higher expression of CD38 was not 
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observed in these cases. Nevertheless, other studies have implicated a high WNT-16 
expression and expression of alternative negative indicators ZAP70, CD49d, and 
CD49b to contribute to the poor prognosis indicated in stereotyped IGHV3-21 
patients.147 
 
 
Figure 4.1 A.  Kaplan Meier curve showing overall survival and time to treatment in IGHV3-
21 patients. 
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In summary, using a population-based cohort we reconfirm the geographic bias in 
IGHV3-21 gene frequency previously identified in Scandinavia. Moreover, we 
determined that IGHV3-21 patients experience an inferior outcome independently of 
stereotypy. Regarding the prognostic role of stereotypy in IGHV3-21 CLL, further 
large collaborative studies are needed before a definite conclusion can be made since 
a large heterogeneity among published studies exists. 
4.2: Paper II: High density array screening for genomic events 
in stereotyped subsets of CLL 
Although the advancement of new prognostic markers has allowed improved 
subdivision of CLL, the causes of CLL still remain unknown and there is yet no 
single genetic event indicated in all cases. Since the existence of multiple subsets of 
CLL expressing ‘stereotyped’ BCRs implies a role for antigen(s) in CLL,5,6 and 
considering ‘stereotypy’ may influence CLL clinical course, it was of interest to 
determine if biases existed in the genomic profiles of stereotyped patients. As 
mentioned, both the stereotyped IGHV3-21 subset #2 and IGHV3-21 non-stereotyped 
counterparts are associated with a poor overall survival.137,150,152 Moreover, some 
studies report subset #2 to be associated with a more progressive disease5,6,149 relative 
to non stereotyped IGHV3-21, a finding we did not find evidence of among our own 
cohort of Swedish stereotyped IGHV3-21 patients in Paper I. On the other hand, 
stereotyped IGHV4-34 subset #4 is associated with an indolent disease course 
compared to its non-stereotyped counterparts.5,6 Regarding IGHV4-34 subset #16, 
little is known about this less commonly encountered subset. Thus, the aim of Paper 
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II was to perform a detailed genetic characterization of clinically divergent 
stereotyped CLL subsets using high-resolution SNP arrays, to identify genetic events 
that may give clues to their pathogenesis and diverse clinical outcomes. In particular 
this study focused on the comparison of poor prognostic IGHV3-21 subset #2 and 
favourable prognostic IGHV4-34 subset #4 patients. In an attempt to identify 
stereotyped specific events, the genetic profiles of stereotyped subsets were compared 
to their non-stereotyped counterparts and a general CLL cohort. 
SNP analysis revealed a higher number of poor prognostic IGHV3-21 samples to 
carry alterations, i.e. 97% of subset #2 and 92% of non-subset #2 samples. In 
contrast, the proportion of subset #4 samples bearing alterations was considerably 
less (76%). Similarly, 75% of subset #16 samples carried aberrations, whereas 88% 
of the more clinically heterogeneous non-subset 4/16 cases displayed alterations. 
Besides the marked differences in the overall frequencies of samples affected with 
CNAs, differences in the genomic complexity regarding the number, type and size of 
alterations encountered were noted between the study groups. Overall, subset #2 and 
non-subset #2 displayed a higher average number of aberrations compared to subset 
#4. More specifically, 48% of subset #2 and 39% of non-subset #2 samples carried ≥3 
alterations compared to 18% of subset #4 and 13% of subset #16 (Figure 4.2 A). In 
fact, the majority (53%) of subset #4 patients carried only one alteration. The 
increased genome complexity observed for IGHV3-21 patients, particularly for subset 
#2, can be partially accounted for by the high frequency of the known recurrent 
alterations observed. Interestingly, known recurrent alterations were detected in 90% 
of subset #2 cases compared to, 54% of non-subset #2 patients. More noticeably, a 
low frequency of the known recurrent alterations was seen among the favourable 
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prognostic subset #4 patients (35%). Similarly, a low frequency was detected in 
subset #16 (25%). However, IGHV4-34 non-subset 4/16 patients displayed a similar 
frequency of known recurrent alterations compared to IGHV3-21 patients (59%). 
 
 
 
Figure 4.2 A. Level of genomic complexity (CNA number and size). 
 
Notably, poor prognostic deletions of 11q were more frequent in subset #2 and non-
subset #2 (31% and 23%) relative to subset #4 and IGHV4-34 non-subset #4/16 
patients (0% and 12%). Furthermore, deletions of 13q were particularly high in subset 
#2 cases and concurrent alterations at 11q and 13q were also found to be common in 
these patients. In contrast, deletion of the good prognostic marker del(13q) was the 
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only known recurrent aberration detected in subset #4 (35%) (Table 4.2 A). On 
considering the larger number of alterations and the high frequency of poor genomic 
markers carried by subset #2 in comparison to subset #4 patients, these findings 
suggest that subset #2 are more likely to acquire genomic events relative to subset #4. 
These events may represent important genetic events during the pathogenesis of 
IGHV3-21 CLL particularly when considering the frequent finding of concurrent 11q 
and 13q deletions, especially in subset #2 cases (Table 4.2 A). Hypothetically, these 
aberrations may be acquired during the phase of active stimulation by (unknown) 
antigens, which trigger the IGHV3-21 precursor cell to undergo rapid cell division 
and hence, under such proliferative pressure acquire such clonal alterations. In 
addition, it is interesting to speculate that these observations may account for the 
adverse clinical outcome reported for IGHV3-21 CLL, particularly for subset #2 
patients. 
 
Table 4.2 A. Known genomic alterations in IGHV3-21 and IGHV4-34 subsets compared to a 
general CLL cohort. 
Subset/ 
non-subset 
del(11q) 
(poor 
prognosis) 
del(13q) 
(good 
prognosis) 
trisomy 12 
(intermediate  
prognosis) 
del(17p) 
(poor  
prognosis) 
Subset #2 31% 79% 0 0 
Non-subset #2 23% 31% 23% 7.7% 
Subset #4 0 35% 0 0 
Subset #16 13% 0 13% 0 
Non-subset 
#4/16 
12% 44% 6% 3% 
General CLL 
cohort 
13% 54% 11% 4% 
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Recent reports suggest that not only the type of alteration but the size of the alteration 
and the nature of their breakpoints influence clinical outcome. In this study, alteration 
size accounted for another layer of genomic complexity. Size distribution analysis 
showed subset #2 and non-subset #2 patients to have a higher number of alterations 
greater than 1Mb in size compared to the other subgroups, particularly subset #4. 
This can be accounted for by the high frequency of large known recurrent alterations 
seen in IGHV3-21 patients, particularly in subset #2. However, further investigations 
revealed that both subset #2 and non-subset #2 have similar average number of 
CNAs/sample comparable to the level observed in our recent array-based study on 
Swedish CLL.183 Hence, subset #2 and non-subset #2 cases do not appear to be more 
complex when accounting for all genomic alterations compared to other CLL patients 
in general. Their crux appears to come from their susceptibility to acquire known 
recurrent alterations and larger sized alterations, which might be reflective of their 
more active proliferative status. 
On the other hand, subset #4, #16 and non-subset #4/16 showed a higher prevalence 
of smaller alterations <1Mbp, owing to the lack of large recurrent alterations such as 
del(11q), trisomy 12 and del(17p) in these groups. Additionally, 13q deletions in 
subset #4 were shown to be of a smaller average size compared to those encountered 
in the IGHV3-21 groups. Overall, on considering the lower number and size of 
alterations in subset #4 and the lack of poor prognostic alterations compared to subset 
#2, these features suggest that subset #4 patients are less likely to accumulate 
genomic alterations. This is suspected to be due to a low proliferative drive stemming 
from the IGHV4-34 BCR. Altogether, the lack of such genomic aberrations may in 
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part be responsible for the indolent disease course experienced by subset #4 CLL 
patients. 
Novel events were identified on chromosomes 2q, 7q and 14q in IGHV4-34 patients; 
however these were not attributed to any particular subset. Recurrent gains at 2q and 
losses at 3p were demonstrated in two subset #2 cases. Recurrent CNN-LOH events 
were mainly detected on chromosome 13q, although independently of stereotypy 
status. 
This study concludes that genomic aberrations were more common in subset #2 and 
non-subset #2 compared to subset #4. The particularly high frequency of del(11q) in 
subset #2 may be linked to the adverse outcome reported for these patients. In 
contrast, the lower prevalence and size of CNAs and the absence of poor-prognostic 
aberrations in subset #4 may reflect the indolent disease course seen in these patients. 
4.3: Paper III: Array-based methylation profiling in prognostic 
subsets of CLL 
Aberrant DNA methylation is a key component in augmenting tumorigenesis, where 
genome-wide hypomethylation and regional hypermethylation of tumor suppressor 
gene (TSG) promoters are signature characteristics of many cancers.286 As 
mentioned, in CLL, the candidate gene approach has revealed a significant 
association linking promoter methylation to transcriptional silencing for a small 
number of individual gene promoters, namely DAPK1,309 ZAP70308 and TWIST-2.307 
Since the global methylation profiles of CLL were yet to be discovered, Paper III 
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sought to investigate genome wide DNA methylation patterns in three divergent CLL 
prognostic subgroups; IGHV mutated, unmutated and IGHV3-21 patients. 
Considering the clinical and biological diversity of these subgroups, Paper III set out 
to perform a detailed genome wide, albeit somewhat promoter biased, epigenetic 
characterization using the Illumina 27K high-resolution DNA methylation 
microarray, as an important means to identify differentially and aberrantly methylated 
genes that may play a role in their pathogenesis and diverse clinical outcome. 
Moreover, as methylation changes are reversible with the use of de-methylating 
agents, whole genome scanning may help identify new therapeutic targets in CLL. 
Hence, Paper III investigated the significance of DNA methylation in regulating gene 
promoters by re-inducing the expression of methylated TSGs using the methyl-
inhibitor 5-aza-2’-deoxycytidine and the histone deacetylase inhibitor TSA. 
Corroborating other studies, Paper III demonstrated that CLL is hypomethylated 
compared to normal healthy individuals on the global level.304-306 Furthermore, by 
applying stringent bioinformatic approaches we identified for the first time distinct 
differential methylation profiles in divergent CLL prognostic subgroups. A number of 
significantly differentially methylated genes occupying key cellular pathways and 
functions were revealed between the studied subgroups. For instance, 7 TSGs were 
preferentially methylated and potentially silenced in the poor prognostic IGHV 
unmutated subgroup (e.g. VHL, ABI3) (Table 4.3 A).363,364 In contrast, these genes 
remained unmethylated and hence potentially expressed in the favourable prognostic 
IGHV mutated CLL. That said, the IGHV mutated subgroup did display methylation 
of 2 TSGs, PPP1R3A365 and WISP3366 that were unmethylated in IGHV unmutated 
patients (Table 4.3 A). Similarly, most methylated TSGs found in the IGHV 
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unmutated subgroup were found to be unmethylated in IGHV3-21 patients, one 
exception was the preferential methylation of the SLC22A18 gene.367 These 
observations suggest that the specific methylation patterns of certain TSGs may play 
a role in the pathogenic pathways that lead to these clinically divergent subgroups. 
That notwithstanding, many of the TSGs identified in this study have been implicated 
in several other cancers, however, their role in CLL has yet to be determined (Table 
4.3 A). 
Table 4.3 A. A brief summary of the differentially methylated genes identified between 
IGHV mutated and IGHV unmutated CLL 
Gene  
function 
IGHV  
Mutated- 
CLL 
IGHV  
Unmutated-CLL 
Examples 
Aiding  
tumourigenesis 
Methylated Unmethylated ADORA3368 
ANGPT2369 
Suppressing 
tumourgenesis 
Unmethylated Methylated VHL363, ABI3364  
LCOD1370 
Anti-apoptotic Methylated Unmethylated BCL287 
Pro-apoptotic 
genes 
Unmethylated Methylated BCL10371 
 
Certain cellular pathways, such as NFκB, PI3K/Akt and MEK/ERK, are dysregulated 
in CLL B cells leading to activation of anti-apoptotic pathways.116,117,120,372,373 Our 
data strengthens this idea and further indicates that certain genes involved in such 
‘proliferative’ pathways may be regulated by DNA methylation in CLL. For example, 
genes activating the NFκB pathway, such as ADORA3368 and CARD15,374 were 
specifically unmethylated in the unmutated CLL subgroup. Similarly, the 
LOC340061375 and PRF1376 genes, which activate the NFκB and MAPKinase 
pathways, respectively, were unmethylated and therefore potentially expressed in 
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poor-prognostic IGHV3-21 CLL compared to IGHV mutated CLL. In line with these 
findings, genes repressing the NFκB pathway (LCOD1 gene)370 and MAPKinase 
(ZNF540 gene)377 pathways were generally methylated in both IGHV unmutated and 
IGHV3-21 samples in contrast to IGHV mutated CLL. Again most genes have not 
been associated with CLL, while many are known to be involved in the 
tumourigenesis of several other cancers and leukaemias. 
Genes known to facilitate tumourigenesis within other cancer types, such as IFNB1378 
and IL17RC,379 were noted to be preferentially unmethylated in the IGHV unmutated 
and IGHV3-21 CLL subgroups in comparison to IGHV mutated CLL. Similarly the 
LMO2 oncogene380 and RASGRP3381 which regulate B cell proliferation by 
facilitating B-cell receptor-Ras signaling, were unmethylated in IGHV3-21 samples. 
Thus, the above data indicates that poor-prognostic CLL subsets favor expression of 
genes aiding tumor proliferation. 
Interestingly, array analysis provided insights into the deregulation of anti- and pro-
apoptotic genes in IGHV mutated CLL. For instance, PLD1, a known anti-apoptotic 
gene,382 remained unmethylated in IGHV mutated CLL samples. On the other hand, 
pro-apoptotic genes such as BCL10371 and TP5313383, were methylated in IGHV 
mutated samples unlike IGHV unmutated CLL. 
In short, genes related to prognosis, for instance the ANGPT2369 gene, which has been 
implicated in progressive CLL disease states were shown to be preferentially 
methylated in the favourable prognostic mutated CLL cases while being 
unmethylated in unmutated CLL (Table 4.3 A). In addition, the NGFR gene which 
has been associated with a favorable prognosis in ALL,384 was shown to be 
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unmethylated in IGHV mutated CLL and showed increased expression on the RNA 
level within this subset. 
Independent verification of array results was performed for a select number of genes 
of different functionalities using an independent CLL sample set. MSP-PCR semi-
quantitatively verified the methylation status of four methylated genes (PRF1, 
ADORA3, IGSF4 and BCL10), RQ-PCR demonstrated the correlation between gene 
expression and methylation status for 4 genes (eg. VHL, ABI3 and NGFR) in an 
independent CLL cohort and finally, bi-sulfite sequencing further quantified the 
degree of methylation for two genes (ABI3 and VHL). 
Finally, through the inhibition of DNA methylation using methyl- and HDAC 
inhibitors, this study evidenced the induced expression of methylated TSGs (e.g. 
IGSF4, ABI3 and VHL) in unmutated CLL primary samples. In general, although a 
low induction of gene expression was observed with methyl inhibitor treatment only, 
a more pronounced effect was seen when the methyl inhibitor and histone acetyl 
inhibitor drugs were applied in combination. That said, the low induction can be 
partially explained by the fact that CLL primary cells do not proliferate at a high rate 
under in vitro conditions. These data indeed strengthen the role of DNA methylation 
in regulating promoter expression and open up the possibility of targeted therapy in 
CLL (Figure 4.3 A). 
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Figure 4.3 A. Re-expression of DNA methylated tumour suppressor gene ABI3 using methyl 
inhibitor DAC (5-aza-2’ deoxycytidine) and histone acetyl inhibitor Tricostatin (TSA). 
In conclusion, Paper III shows distinct methylation profiles encompassing a number 
of candidate genes involved in cellular pathways regulating proliferation and 
apoptosis in IGHV unmutated/mutated and IGHV3-21 CLL and thus underlines the 
critical role of epigenetic changes during leukemogenesis. 
4.4: Paper IV: DNA methylation screening of CLL samples over 
time and within different CLL compartments 
On identifying differential methylation profiles in IGHV mutated and unmutated CLL 
in Paper III, we set out to further investigate their methylation profiles using a higher 
resolution 450K global DNA methylation microarrays. More specifically, we aimed 
to determine whether the DNA methylation profiles of these subgroups changed over 
time during the course of disease and whether DNA methylation of CLL cells 
differed according to the anatomical site from which the cells resided. The first part 
of this study, in accordance with Paper III, again identified IGHV mutated and 
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unmutated CLL to have differential DNA methylation profiles, albeit on a larger scale 
than previously reported. Specifically we found 2239 differentially methylated sites 
between these subgroups compared to a mere 99 sites identified previously. We found 
a relatively even distribution of differentially methylated sites across the whole 
genome. However, we noted that the largest proportion of differentially methylated 
sites was located outside of the CpG islands and within gene bodies. Only recently 
with the advent of whole genome analysis has the relevance of this latter finding 
come to light. Traditionally DNA methylation analysis has solely focused on CpG 
islands, particularly within gene promoters, since it is here that gene regulation is 
primarily regulated. In Paper III, we identified DNA methylation of ADORA3, 
positioned approximately 1kb away from the promoter, to have a regulatory function 
on gene expression. On a much larger scale Irizarry et al295 further corroborates this 
finding, showing the majority of altered DNA methylation sites in colon cancer to 
reside outside of CpG islands in regions up to 2kb distant from the CpG island in 
regions called CpG island shores. Moreover, these sites were shown to correlate to 
gene expression. 
Gene ontology analysis identified a number of enriched physiological and molecular 
functionalities, most of which have not been implicated in CLL before. Many genes 
were known as members of established signaling pathways, whereas others were 
shown to be involved in other cancers. For instance, CpG sites within DNA repair 
genes, DNA methyltransferase genes DNMT3B,264 members of the polycomb 
complex EED,385 JAIRD2386 and polycomb target genes were detected as 
differentially methylated. Specifically 230 CpG sites covering 158 polycomb target 
genes previously characterized in embryonic fibroblasts387 presented as differentially 
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methylated between IGHV mutated and unmutated CLL. Approximately half of the 
sites presented with a higher methylation level in unmutated CLL, whereas the other 
half were found to have a higher level within the mutated subgroup. Preferential 
methylation of developmental polycomb target genes has been frequently recognised 
in other forms of cancer.388,389 That said, the exact biological relevance of this finding 
is largely unexplored in cancer. What is known is that tumor-specific targeting of de 
novo methylation at these targets is pre-programmed by an established epigenetic 
system namely H3K27me3 that normally has a role in marking embryonic genes for 
repression. Unlike normal cells, the EZH2 polycomb complex maintaining 
H3K27me3 recruits DNA methyltransferase to these sites in cancer cells.389 
A focused search for genes formerly implicated in CLL, found a number of survival 
related (TCF3,390 LEF1391), proliferation (CD80,392 CD86393) and apoptosis 
(FAS)394and BCR signaling related genes (IBTK).395 Moreover, 12 differentially 
methylated genes identified in Paper III were found to overlap to this present study 
and were shown to be largely concordant in terms of methylation status. For example, 
the preferential methylation of tumour suppressor genes ABI3364 in IGHV unmutated 
and WISP3366 in IGHV mutated subgroups was re-confirmed. In support of Corcoran 
et al,308 we found the CLL prognostic gene ZAP70,166 to be preferentially methylated 
in IGHV mutated patients relative to unmutated cases. Furthermore, Corcoran et al,308 
have shown that methylation of ZAP70 correlates well to ZAP70 expression. 
Recently, methylation analysis of ZAP70 intron 1 by pyrosequencing has been shown 
to be a robust method correlating to ZAP70 and CD38 expression, IGHV mutation 
status, overall survival and time to treatment. Given the lack of sufficient 
standardisation with current flow cytometry quantitation methods, quantification by 
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pyrosequencing can provide an alternative mode of analysis.396 For the first time, 
CLL prognostic genes LPL170,173 and CLLU1177,178,394 were noted to be differentially 
methylated between IGHV mutated and unmutated CLL. More specifically, higher 
DNA methylation within the gene body of CLLU1 and the transcription start site 
TSS1500 and gene body region of LPL in IGHV mutated CLL relative to IGHV 
unmutated patients was demonstrated. In recent times, expression of both LPL and 
CLLU1 has been noted to be higher in IGHV unmutated patients compared to IGHV 
mutated cases.177,178,267 In CLL, high expression of these genes is associated with 
poor clinical outcome.170,173 In view of these observations, it is interesting to 
speculate that perhaps DNA methylation of these genes may contribute to their 
differential expression seen in CLL. 
One of the enriched canonical pathways highlighted through IPA analysis was the 
molecular mechanisms of cancer pathway. Within this IPA derived pathway, we 
identified pathways previously implicated in CLL namely the NF-κB/TNFR1 and 
TGF-ß pathways. Of particular interest is the TNF/NF-κB pathway. Here ten 
members of this pathway were found to be differentially methylated. For instance, a 
CLL autocrine growth factor TNF,397,398 TNFRSF8 (CD30), a receptor for thioredoxin 
(Trx)399 a survival factor for CLL cells400,401 and two TNF receptor genes, TNFSF1A 
and TNFRSF1B, recently shown to be redox-controlled by protein-disulfide 
isomerase (PDI) in complex with thioredoxin-1 (Trx1), were found to be 
differentially methylated in mutated and unmutated CLL. Although these findings are 
interesting, relating the role of DNA methylation to the functionalities of such a 
pathway in CLL is difficult. The variable incidence of multiple or single CpG sites 
across genes at variable locations along different gene regions (gene body, TSS1500 
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etc) makes interpretation challenging. Sometimes multiple CpG sites across the same 
gene at different regions will have variable methylation values. These challenges are 
further complicated by the fact that the biologically relevant level of DNA 
methylation needed to effect gene expression is currently unknown. 
With the prospect of aberrant DNA methylation marks as candidate prognosticators, 
it is essential that such marks be stable in terms of DNA methylation level. To date, a 
limited number of studies exist documenting the stability of DNA methylation over 
time. Of the few studies available variable results ensue. This is perhaps in part 
reflective of the different diseases and nature of the cohort studied in these reports. 
However, more pressing inconsistencies stem from the alternative techniques 
employed and differences in the processing and interpretation of DNA methylation 
data. For example, a report examining bladder cancer metachronous tumours from 
two individuals, has shown DNA methylation to be relatively stable over time both 
within the individual and between patients.329 In contrast, a study by Bjornsson et 
al328 has identified inter-individual age variation and differences occurring over time 
within individuals, that would otherwise be over-looked by group averaging of the 
data. These changes were shown to be clustered within family members highlighting 
the possibility that genetic background may effect DNA methylation changes.324,328 
Nevertheless, a study of DNA methylation in 40 monozygotic twins found 35% of 
twin couples to have a disconcordant level of total DNA methylation, particularly 
those over the age of 28 years.330 In this instance, different environmental influences 
and exposures were thought to play a role. 
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In light of the above findings we dedicated the second part of the study to examine 
DNA methylation over time in paired CLL diagnostic and follow-up patients. Based 
on average DNA methylation values across the groups, this study for the first time 
established that global DNA methylation is relatively stable over time. Both IGHV 
mutated and unmutated patients incurred only a few, small recurrent changes over 
time. Interestingly however, on analyzing the intra-individual changes a larger 
difference in the number of non recurrent differentially methylated sites were noted 
over time between IGHV mutated and unmutated cases, that would otherwise be 
missed on group averaging of the data. More specifically, intra-individual analysis of 
IGHV unmutated patients showed a large difference whereas intra-individual 
investigation of IGHV mutated patients showed no significant difference in the 
number of non-recurrent differentially methylated sites over time (Figure 4.4 A). That 
said, in global terms, these non-reccurent changes in IGHV-umutated cases equated 
to a very small overall global change (<1%), when taking into account the 485,000 
sites available on the array.  Nevertheless, it is interesting to speculate that perhaps 
these findings are reflective of the more indolent and aggressive disease course 
associated with IGHV mutated and unmutated patients respectively. Notably, global 
DNA methylation within IGHV unmutated patients over time was relatively stable 
despite the implementation of treatment between diagnosis and follow-up. Thus it 
appears that DNA methylation of CLL cells is not largely effected by therapy, at least 
not in respect to overall DNA methylation. 
It is difficult to ascertain whether or not some of these non-recurrent DNA 
methylation changes act as driver epi-mutations causing the expansion of the CLL 
clone. A more likely explanation, given the lack of recurrent changes over time, 
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indicates that the changes encountered merely act as passenger events arising from 
the higher proliferative nature in the preexisting unmutated clone. Nevertheless, it is 
interesting to speculate that perhaps these changes may contribute to CLL 
leukemogenesis by contributing to overall epigenomic instability. 
 
 
Figure 4.4. Box plot visualizing the difference in number of non recurrent differentially 
methylated sites overtime within and between patient matched diagnostic and follow-up 
IGHV mutated and IGHV unmutated CLL patients. 
 
Resting PB CLL cells are known to communicate with a pro-survival 
microenvironment in proliferation centers of the LN resulting in proliferation 
(~1%/day) of the CLL clone.89 Recently, a higher expression of genes involved in 
proliferation and active BCR signaling were shown in the LN relative to the blood of 
patient-matched CLL samples.118 In light of the anti-correlation of DNA methylation 
to gene expression, we hypothesized that DNA methylation may partake in the 
mechanism of differential gene expression seen within the different compartments of 
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CLL. Furthermore, in mind of the possibility of aberrant DNA methylation marks as 
candidate prognostic markers, it is important to establish whether such marks are 
stable over different sampling sites. Therefore, in the third part of the study, we 
examined the DNA methylation profiles of patient-matched CLL cells derived from 
the PB and LN, to acertain the influence of the microenvironment on CLL patient 
DNA methylation profiles. This study for the first time found that global DNA 
methylation is rather similar in patient matched PB and LN samples. Only few, small 
recurrent changes were identified. Moreover, the number of non-recurrent changes 
although relatively low in global terms (<1%), were found to vary in number across 
the intra-individual PB and LN pairs. Therefore it seems that unlike gene expression, 
DNA methylation in CLL cells is not heavily influenced by the microenvironment. 
 
In sum, on a larger scale to Paper III, this study reconfirms IGHV mutated and IGHV 
unmutated CLL to have differential methylation profiles. More specifically, CLL 
prognostic genes, polycomb target genes, and key members of TGF-ß and NF-
κB/TNFR1 pathways were noted to be differentially methylated. Finally, global DNA 
methylation was shown to be relatively stable over time and to be remarkably similar 
in CLL cells derived form different anatomical CLL compartments. 
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5: CONCLUSIONS 
This thesis applied IGHV gene sequencing and high resolution SNP and DNA 
methylation microarray techniques in order to interrogate genetic and methylation 
events that may contribute to CLL leukemogenesis in diverse prognostic subgroups 
and subsets of CLL. 
5.1. Paper I 
• Within the Swedish population-based cohort studied, the geographic bias in 
IGHV3-21 gene frequency previously identified in Sweden was validated, albeit 
at a lower frequency than formerly reported in our hospital- based cohort study. 
 
• IGHV3-21 patients were shown to have an inferior outcome independently of 
stereotypy. Hence, no prognostic value could be attributed to IGHV3-21 
stereotypy status. 
5.2: Paper II 
• Poor prognostic IGHV3-21 subset #2 patients commonly carried more genomic 
aberrations and larger sized alterations compared to favourable prognostic 
IGHV4-34 subset #4 patients. Thus, it appears that subset #2 patients are more 
genomically complex relative to subset #4. 
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• IGHV4-34 subset #4 patients exclusively carried the favourable prognostic 
del(13q) marker, whereas poor prognostic subset #2 patients carried a high 
frequency of the poor prognostic del(11q) marker. Hence, these findings may in 
part be reflective of the favourable prognosis seen in subset #4 and the adverse 
outcome seen in subset #2 patients. 
5.3. Paper III 
• Distinct differential methylation profiles were detected in three divergent 
prognostic subsets of CLL, IGHV mutated, unmutated and IGHV3-21. 
Differentially methylated genes, such as TSGs, were preferentially methylated in 
the poor prognostic IGHV unmutated subgroup compared to the favourable 
prognostic IGHV mutated CLL. Moreover, genes involved in cell proliferation 
were specifically unmethylated in the poor prognostic IGHV unmutated and 
IGHV3-21 subgroups. Hence, these findings suggest that the methylation status of 
certain key cellular genes may contribute to CLL pathogenesis and the divergent 
clinical outcome seen in certain CLL subsets. 
 
• Through the use of methyl inhibitor and histone deacetylation drugs, the re-
expression of methylated TSGs (ABI3, VHL) was demonstrated. Hence the 
reversible nature of DNA methylation was functionally established. 
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5.4: Paper IV 
• On a larger scale to Paper III, this study reconfirmed that IGHV mutated and 
IGHV unmutated CLL are characterized by differential methylation profiles. 
Differentiallly methylated sites between these subgroups primarily presented 
outside of CpG islands. Preferential DNA methylation of CpG sites within known 
CLL prognostic genes CLLU1 and LPL was notably higher in IGHV mutated 
cases relative to IGHV unmutated patients. Key members of TGF-ß and NF-
κB/TNFR1 pathways and large numbers of polycomb targets were also shown to 
be differentially methylated between IGHV mutated and unmutated CLL. 
 
• Global DNA methylation in paired diagnostic and follow-up IGHV-UM (treated) 
CLL and IGHV-M (untreated) CLL patients was deemed to be relatively stable 
over time. Hence, this finding supports the notion that abberant DNA methylation 
events are early events in CLL pathogensis. 
 
• DNA methylation changes in patient-matched peripheral blood and lymph node 
samples were found to be relatively similar. Hence, it seems the differences in the 
PB and LN micro-environment does not heavily influence the DNA methylation 
profiles of CLL cells. 
 
Taken together, these studies provide a greater insight into the genetic alterations and 
DNA methylation events occurring in divergent CLL prognostic subgroups. 
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